

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Heritability of cardiovascular health across three generations in South Africa: the Birth to Twenty-Plus cohort

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-059910
Article Type:	Original research
Date Submitted by the Author:	11-Dec-2021
Complete List of Authors:	<p>Ware, Lisa; University of the Witwatersrand, SAMRC Developmental Pathways for Health Research Unit; University of the Witwatersrand, DSI-NRF Centre of Excellence in Human Development  Maposa, Innocent; University of the Witwatersrand Faculty of Health Sciences, Division of Epidemiology and Biostatistics, School of Public Health  Kolkenbeck-ruh, Andrea; University of the Witwatersrand, SAMRC Developmental Pathways for Health Research Unit  Norris, Shane; University of the Witwatersrand, SAMRC Developmental Pathways for Health Research Unit; University of Southampton, Global Health Research Institute, School of Human Development and Health &amp; NIHR Southampton Biomedical Research Centre  Soepnel, Larske; University of the Witwatersrand, SAMRC Developmental Pathways for Health Research Unit; Julius Center for Health Sciences and Primary Care, Julius Global Health  Crouch, Simone; University of the Witwatersrand, SAMRC Developmental Pathways for Health Research Unit  Juliana, Kagura; University of the Witwatersrand Faculty of Health Sciences, Division of Epidemiology and Biostatistics, School of Public Health  Naidoo, Sanushka ; University of the Witwatersrand, SAMRC Developmental Pathways for Health Research Unit  Smith, Wayne; North-West University - Potchefstroom Campus, Hypertension in Africa Research Team (HART); SA MRC Unit for Hypertension and Cardiovascular Disease  Davies, Justine ; University of Birmingham, Institute of Applied Health Sciences; Stellenbosch Institute for Advanced Study, Wallenberg Research Centre at Stellenbosch University</p>
Keywords:	Hypertension < CARDIOLOGY, CLINICAL PHYSIOLOGY, PREVENTIVE MEDICINE, PUBLIC HEALTH, Cardiovascular imaging < RADIOLOGY & IMAGING

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Heritability of cardiovascular health across three generations in South Africa: the Birth to Twenty-**  
4 **Plus cohort**  
5

6  
7 Lisa J Ware<sup>1,2</sup>, Innocent Maposa<sup>3</sup>, Andrea Kolkenbeck-Ruh<sup>1</sup>, Shane Norris<sup>1,2</sup>, Larske Soepnel<sup>1,4</sup>, Simone  
8 Crouch<sup>1</sup>, Juliana Kagura<sup>3</sup>, Sanushka Naidoo<sup>1</sup>, Wayne Smith<sup>5</sup>, Justine Davies<sup>6</sup>.  
9

10  
11  
12  
13 <sup>1</sup>SAMRC/Wits Developmental Pathways for Health Research Unit, Faculty of Health Sciences,  
14 University of the Witwatersrand, Johannesburg 2000, South Africa.

15  
16 <sup>2</sup>DSI-NRF Centre of Excellence in Human Development, University of the Witwatersrand,  
17 Johannesburg 2000, South Africa.

18  
19 <sup>3</sup>Division of Epidemiology and Biostatistics, School of Public Health, Faculty of Health Sciences,  
20 University of the Witwatersrand, Johannesburg, 2000, South Africa

21  
22 <sup>4</sup>Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center  
23 Utrecht, Utrecht University, Utrecht, The Netherlands.

24  
25 <sup>5</sup>Hypertension in Africa Research Team (HART), North-West University, South Africa. South African  
26 Medical Research Council: Unit for Hypertension and Cardiovascular Disease, North-West University,  
27 South Africa.  
28

29  
30 <sup>6</sup>Stellenbosch Institute for Advanced Study, Wallenberg Research Centre at Stellenbosch University,  
31 Stellenbosch 7600, South Africa; MRC/Wits Rural Public Health and Health Transitions Research Unit,  
32 School of Public Health, University of the Witwatersrand, Johannesburg, South Africa; Institute of  
33 Applied Health Sciences, University of Birmingham, Birmingham, UK  
34

35  
36  
37 Running title: Vascular health heritability in South African families.  
38

39 Word count: 4236 excluding abstract and references

40 Number of tables: 3

41 Number of figures: 0

42 Number of supplementary digital content: 1  
43

44  
45 Correspondence: Lisa Ware, SAMRC/Wits Developmental Pathways for Health Research Unit, Faculty  
46 of Health Sciences, University of the Witwatersrand, Chris Hani Baragwanath Academic Hospital, 26  
47 Chris Hani Road Soweto Johannesburg, South Africa. Tel: +27 (0)10 447 3721, email  
48 lisa.ware@wits.ac.za  
49

## Abstract

Objectives: Cardiovascular disease is increasing in many low-middle income countries, including those in Africa. To inform strategies for the prevention of cardiovascular disease in South Africa, we sought to determine the broad heritability of phenotypic markers of cardiovascular risk across three generations.

Design: A cross-sectional study conducted in a longitudinal family cohort.

Setting: Research unit within a tertiary hospital in a historically disadvantaged, large urban township of South Africa.

Participants: 195 individuals from 65 biological families with all three generations including third generation children aged 4-10 years were recruited from the longest running intergenerational cohort study in Africa, the Birth to Twenty Plus cohort. All adults (grandparents and parents) were female, while children were male or female.

Primary and secondary outcome measures: The primary outcome was heritability of blood pressure (BP, brachial and central pressures). Secondary outcomes were heritability of arterial stiffness (pulse wave velocity), carotid intima media thickness (cIMT), and left ventricular mass indexed to body surface area (LVMI).

Results: While no significant intergenerational relationships of BP or arterial stiffness were found, there were significant relationships in LVMI across all three generations ( $p < 0.04$ ), and in cIMT between grandparents and parents ( $p = 0.0166$ ). Heritability estimates were 23-44% for cIMT and 21-39% for LVMI.

Conclusions: Structural indicators of vascular health, which are strong markers of future clinical cardiovascular outcomes transmit between generations within African families. Identification of these markers in parents may be useful to trigger assessments of preventable risk factors for cardiovascular disease in offspring.

**Keywords:** Vascular diseases, pulse wave analysis, heart disease, family, South Africa

### Strengths:

- Intergenerational transmission was evaluated for a range of indicators of cardiovascular health within urban African families
- The sample included biological family members from three generations
- Heritability estimates were compared for three commonly used statistical methods.

### Limitations:

- The sample size is a limitation with the random family statistical method used to increase the numbers of comparisons available.
- Only maternal family members were included.

### Introduction

Within South Africa, a quarter of all adults are hypertensive and one in five deaths are from cardiovascular disease (CVD)<sup>1</sup>. CVD mortality and morbidity are set to rise with increasing life expectancy (now at 64 years; an increase of 10% in the last decade)<sup>2</sup>, and increasing levels of overweight and obesity (68% women, 31% men)<sup>3</sup>. Much focus is placed on detecting and treating CVD, but with limited healthcare resources, pragmatic approaches are needed including primary prevention in younger, at-risk individuals to prevent CVD<sup>4</sup>.

There is evidence that strong predictors of future adverse cardiovascular outcomes (such as heart attacks and strokes) may be transmitted through biological families so that measures in parents or grandparents may identify children at future risk<sup>5</sup>. Early vascular predictors of CVD outcomes include both structural (e.g. thickening or stiffening of arterial walls, cardiac hypertrophy) and functional changes (e.g. elevated blood pressure)<sup>6-10</sup>. Hypertension is the largest contributor to CVD in Africa, with research showing elevated blood pressure in children as young as 5 years of age<sup>11</sup>. Studies of mono- and dizygotic twins have shown high heritability of systolic and diastolic blood pressure in populations of both African and European descent<sup>12 13</sup>, though heritability may be lower for individuals of African descent<sup>14</sup>. Within South Africa, data is also emerging that blood pressure is heritable across families (parent-child, and sibling pairs)<sup>15</sup>. However, due to the high levels of hypertension in South African adults, hypertension in a family member is unlikely on its own to be a sensitive enough indicator to identify at risk young adults or children for intervention. .

As such, additional measures may be needed to identify those family members most at risk and where early intervention may have greater returns. Evidence from outside of Africa has shown that several other markers of cardiovascular disease risk are heritable. For example, central blood pressures may show stronger heritability than the brachial blood pressures typically measured in routine care;<sup>16</sup> carotid artery structure, function and pathology have been shown as heritable, with diameter and carotid intima media thickness appearing as the most heritable traits;<sup>17-19</sup> arterial stiffness, as assessed by pulse wave velocity, has also been reported as heritable within family studies; and <sup>16 20</sup> findings from echocardiography studies suggest that several cardiac measurement parameters may be

1  
2  
3 heritable within families, including left ventricular (LV) function and structure including LV mass and  
4 LV hypertrophy<sup>21-24</sup>. Indeed, the combination of arterial stiffness and central pressure has been  
5 suggested as a potential tool to investigate risk in nuclear families<sup>25</sup>.  
6  
7

8  
9 However, there is limited evidence from African families to indicate which indicators of cardiovascular  
10 health are most related and therefore, potentially most useful to indicate intergenerational risk within  
11 family units in South Africa. One previous study suggested that echocardiography may be particularly  
12 useful to detect intergenerational transmission of changes in cardiac structure and function in South  
13 African families (parent-child, sibling-sibling pairs)<sup>26 27</sup>, though how this and other vascular measures  
14 are related across children, parents and grandparents in the region is not known. Additionally, the  
15 frequent background of undernutrition and burden of infectious diseases may mean that heritability  
16 estimates are different in Africa to elsewhere.  
17  
18  
19  
20  
21

22  
23 Therefore, we sought to investigate how a range of indicators of cardiovascular health (brachial and  
24 central pressures, arterial stiffness, carotid intima media thickness and echocardiography findings)  
25 were related within three generations (grandparents, parents and children) of African families from  
26 urban South Africa to inform further risk identification and potential targeted CVD prevention efforts.  
27  
28  
29

## 30 **Methods**

### 31 *Study population and sample size*

32  
33 Biological families with three generations (grandmother, mother and child [boy or girl age 4-10 years])  
34 were recruited from the largest and longest running birth cohort study in Africa; the Birth to Twenty  
35 Plus (Bt20-plus) cohort described in detail previously<sup>28 29</sup>. A database of 162 index children (now the  
36 mothers) was drawn from previous Birth to Twenty studies that indicated index children with survival  
37 of their biological mother and birth of a biological child. These index children were then contacted by  
38 telephone to confirm the presence of their biological mother, and a biological child between the ages  
39 of 4 and 9 years, with eligible families invited to take part. Families with participants who were  
40 pregnant, experiencing current acute illness, or with any major congenital disorders were excluded.  
41  
42 The study design was a cross-sectional in-depth assessment of vascular health at a research unit  
43 located in a large hospital in Soweto. Data was collected between August 2019 and March 2020.  
44  
45 Previous work in East African families found high heritability of blood pressure (systolic, diastolic and  
46 pulse pressure  $h^2$  0.37, 0.24, 0.54), though the authors did not assess other vascular measures<sup>30</sup>. Based  
47 on these previous reported levels of heritability between two generations and using the methods of  
48 Klein et al.<sup>31</sup>,  $n=65$  families ( $n=195$  individuals) at  $\alpha=0.05$ , would give 82% power to detect an  $h^2$   
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 of 0.4, and 94% power to detect an  $h^2$  of 0.5 in blood pressure. With three generations, these  
4 estimates may be conservative.  
5

### 6 7 *Ethical considerations* 8

9 Trained researchers who spoke the participant's home language explained the study and all  
10 participants provided written informed consent prior to taking part in the study. For children, the  
11 mother of the child provided written consent, with children age 7 years and above also giving their  
12 written assent to take part. The Human Research Ethics Committee (Medical) of the University of the  
13 Witwatersrand approved the protocol (Ref: M190263). We used the STROBE cohort checklist when  
14 writing our report<sup>32</sup>.  
15  
16  
17  
18  
19

### 20 *Patient and Public Involvement* 21

22 The study design was informed by previous work with two generations from this cohort, where  
23 participants expressed a desire to include additional generations in cardiovascular health  
24 assessments. However, participants were not involved in the study design, recruitment or conduct of  
25 the study. During 2022, a series of workshops are planned with the community to disseminate results  
26 and to explore the co-creation of potential community level interventions.  
27  
28  
29  
30

### 31 *Measurements* 32

33 Standard protocols were used for collection of all data, with the same staff repeating all measures or  
34 assessments of inter-operator variability conducted as described further in the appendix. Medical  
35 history (including antihypertensive medication use) and health behaviours were recorded via self-  
36 report. Tobacco use (daily or occasional current use of both smoked and smokeless tobacco products)  
37 was assessed using questions from the Global Adult and Tobacco Survey<sup>33</sup>. Alcohol use was evaluated  
38 using the World Health Organization Alcohol Use Disorders Identification Test (WHO-AUDIT)<sup>34</sup>, with  
39 hazardous or harmful alcohol use assessed as an AUDIT-C score (first three questions – shortened  
40 form) of  $\geq 3$  and/or a total AUDIT score of  $\geq 8$ .  
41  
42  
43  
44  
45  
46  
47

48 Trained researchers measured height and weight in triplicate to the nearest 0.1cm and 0.1kg using a  
49 portable stadiometer and electronic scale (SECA, Hamburg, Germany). Waist and mid-upper arm  
50 circumference (MUAC) were measured in triplicate to the nearest 0.1cm following standard  
51 measurement protocols<sup>35 36</sup>.  
52  
53  
54

55 All measures were taken in the morning following an overnight fast and with no caffeine or tobacco  
56 for at least 3 hours prior to measurement. Using the Sphygmocor Excel device (AtCor Medical,  
57 Naperville, USA) with appropriate size brachial cuff, brachial blood pressure and resting heart rate  
58  
59  
60



1  
2  
3 were determined, and central arterial pressures (cSBP, cDBP, pulse and mean arterial pressure) were  
4 estimated. Three measurements were taken, with the second and third measures averaged for  
5 analysis. Ultrasound measures were taken in triplicate with the Mindray DC-70 Ultrasound system  
6 (Mindray, Shenzhen China). Further detail for these assessments is provided in the appendix.  
7  
8  
9

### 10 *Analyses*

11  
12  
13 The primary outcome was heritability of blood pressure (BP, brachial and central pressures).  
14 Secondary outcomes were heritability of arterial stiffness (pulse wave velocity), carotid intima media  
15 thickness (cIMT), and left ventricular mass indexed to body surface area (LVMI). All exposure effects  
16 were adjusted for age, height, weight and sex in the regression models, with heritability estimates  
17 adjusted for age.  
18  
19  
20

21  
22 For adults, body mass index (BMI kg/height m<sup>2</sup>) was categorised as follows: <18.5 underweight; 18.5-  
23 24.9 normal weight; 25.0-29.9 overweight; ≥30 obese. Children's BMI was categorised as underweight,  
24 normal, overweight or obese using age- and sex-specific cut-offs from the International Obesity Task  
25 Force (IOTF)<sup>37</sup>. Waist to height ratio was calculated for both adults and children, as this has previously  
26 been shown as a predictor of health risks of obesity across the lifecourse in all ethnic groups<sup>38</sup>. In  
27 adults, prehypertension was defined as 120-139 mmHg systolic or 80-89 mmHg diastolic and not  
28 currently taking antihypertensive medication, while hypertension was defined as a blood pressure ≥  
29 140 mmHg systolic or ≥ 90 mmHg diastolic or currently taking antihypertensive medication. For  
30 children, elevated blood pressure was defined using the age, sex, and height adjusted percentiles of  
31 the American Academy of Pediatrics Clinical Practice Guideline (2017)<sup>39</sup>.  
32  
33  
34  
35  
36  
37  
38

39  
40 The Devereux formula was used to calculate LVM<sup>40</sup> and left ventricular mass index (LVMI) was  
41 calculated as a ratio of LVM indexed to body surface area<sup>41</sup>. Left ventricular hypertrophy (LVH) was  
42 defined as LVMI>95g/m<sup>2</sup> for adult women and LVMI >95th percentile for children. Normality of data  
43 were checked with visual inspection of histograms and the Shapiro-Wilk test<sup>42</sup>.  
44  
45  
46

47  
48 Our analyses followed two stages. Stage 1) determining the association between parent-offspring  
49 pairs for each of the vascular health traits, and stage 2) estimating heritability for traits that exhibited  
50 an association in the parent-offspring pairs. Participant characteristics and the associated vascular  
51 health measurements are also described.  
52  
53

### 54 *Stage 1. Random family method*

55  
56 In this study we used the random family method as described in detail by Usuzaki et al. (2020) and  
57 implemented the analysis based on Heß (2017) randomization inference algorithm<sup>43 44</sup>. We used  
58 resampling of the exposure variable to generate the distribution of parental trait effect on offspring,  
59  
60

controlling for confounding variables as below. We used the classical model generally used to explore heritability in phenotypic traits:

$$y_i = \beta_0 + \tau z_i + \beta X + \epsilon_i$$

where  $y_i$  is the offspring trait,  $\tau$  is the “treatment” effect (regression slope) for  $z_i$ , the parental trait.  $X$  is a matrix of control variables and  $\beta$  the associated coefficients.  $\tau$  is obtained for the original pairs ( $z_i, y_i$ ) and using randomization inference tests, we performed 5000 resampling-based pairs to obtain the distribution of the statistic  $\tau$ , that is, the distribution of random parental trait effect on offspring’s corresponding trait. Randomization inference tests have the advantage that they can handle small sample sizes and do not rely on validity of the specified model regardless of the generated statistic being from the model<sup>43</sup>. Randomization inference also produces the distribution of a test statistic under a designated null hypothesis, thereby allowing us to assess whether the observed (original parent-offspring pair) relationship statistic (regression coefficient) is significantly different and hence the null hypothesis can be rejected in favor of the parental trait having a significant influence on the offspring trait. In brief, regression coefficients were generated for all primary and secondary cardiovascular measures within the biological families: adjusting brachial and central pressures, pulse wave velocity and cIMT for age, height, weight and sex; and adjusting LVMI for age and sex only as it is already indexed to body surface area. Restricted resampling of the data was then employed to generate 5000 random family units ensuring random pairing of parent off-spring biological families. The regression coefficients for each cardiovascular outcome marker were then compared between the family pair and random pairs. Kernel density plots of  $\tau$ -values for original family pairs and random pair  $\tau$ - values were then generated to assess statistical significance of the selected traits.

### Stage 2. Heritability Estimation

For those variables which showed significantly greater association between family members compared with randomly generated pairs using the random family method, heritability estimate(s) were derived using the variance components decomposition method based on the linear mixed effects model (LMM) as all vascular health traits of interest were continuous. The Restricted Maximum Likelihood (ReML) method was used to estimate the variance components and hence heritability. However, due to concerns by Hadfield (2010) and Morrissey (2010) on ReML limitations<sup>45 46</sup>, we additionally implemented the Bayesian method for variance components and heritability estimation<sup>47</sup>, thereby creating a range for each heritability estimate. The basic model (LMM) is:

$$Y|Z,X \sim N(\chi\beta, G\sigma_g^2 + I\sigma_e^2)$$

where additive genetic variance of the trait  $G$  is estimated using relatedness information between individuals or genotypes  $Z$  with both fixed effects  $\beta$  for  $X$  control variables,  $\epsilon_i \sim N(0, \sigma_e^2)$  and random effects following a normal distribution with mean 0 and variance  $G\sigma_g^2$ <sup>48</sup>.  $G$  is the genetic relatedness matrix (GRM) and was estimated using the kinship package in R (R version 4.0.2)<sup>49</sup>. We also used the kinship package to plot the pedigree of one family in our dataset. The Bayesian linear mixed model with polygenic effects ( $g$ ) having the following sampling model:

$$y|\beta, u, \sigma^2 \sim N(X\beta + Zu, \sigma^2 I), \beta \sim N(0, \sigma_\beta^2 B), u \sim N(0, \sigma^2 G)$$

where  $B$  is known and non-singular diagonal matrix and  $\sigma_\beta^2$  as a hyperparameter was used. The  $G$  in  $\sigma^2 G$  is the genetic relatedness matrix estimated through the kinship package for the family relatedness. Note, for this model the likelihood and assumed priors were:

$$y_i \sim N(\mu, \sigma^2 I)$$

$$\mu = X\beta + g$$

$$\beta_j \sim N(0, 1000^2), \forall j = 1, \dots, p$$

$$g \sim N(0, \sigma_g^2 G)$$

$$\sigma_g^2 \sim \text{InvGamma}(s_1, s_2)$$

$$\sigma^2 \sim \text{InvGamma}(s_1, s_2)$$

where  $s_1$  and  $s_2$  are chosen to provide noninformative priors. We used rJAGS and rSTAN to perform markov chain monte carlo (MCMC) and hamiltonian monte carlo (HMC) simulations respectively<sup>48</sup>. Heritability was then computed as  $h^2 = \frac{\sigma_g^2}{\sigma_g^2 + \sigma^2}$ . The marginal distributions of all parameters and estimation of the best linear unbiased predictions (BLUP) for the model were obtained using Gibbs' sampling (MCMC) and the leapfrog integration method (HMC). The samplers made 100000 simulations and only results of the last 90000 were used in the inference. We used two Bayesian paradigms to enable comparisons and manage the inherent uncertainty associated with estimating genetic variance components<sup>45</sup> as well as in using small sample sizes. Age of the participant was used as a control variable for all models and was standardized together with the vascular health traits before estimation to improve efficiency of Bayesian sampling.

## Results

Of the 162 index children identified: n=48 (30%) could not be contacted either as the telephone number had changed or they did not respond to calls or voice messages; n=14 (9%) did not wish to

1  
2  
3 take part; n=5 (3%) were not eligible due to current illness, pregnancy, or a biological child not in the  
4 required age range; n=4 (2%) were no longer residing in Soweto; n=3 (2%) were not available due to  
5 school or work commitments; and n=9 (6%) booked appointments but did not attend. Finally 65  
6 families (49% of those contacted) took part in the study providing n=130 adults and n=65 children and  
7 generating 195 biological pairings: 130 first generation and 65 second generation).  
8  
9

10  
11  
12 Whole family completion rates for the vascular measures were as follows: carotid ultrasound (n=63);  
13 brachial blood pressure, heart rate and pulse wave analysis (n=62); echocardiography (n=59); PWV  
14 (n=40); all vascular measures (n=40). Families with complete anthropometry data and at least one  
15 vascular measurement complete for a family pairing (parent/child, grandparent/parent or  
16 grandparent/grandchild) were included in the analysis as the random family method does not require  
17 all three generations to have data, only that a family has one or more biological pairs with valid  
18 measurements. Descriptive characteristics are presented in Table 1, including the number of adults  
19 and children with successful measurements for each variable.  
20  
21  
22  
23  
24  
25

26 Median age of grandparents, parents and children was 56 years, 29 years and 7 years respectively.  
27 Among adults, 92% of grandparents and 77% of parents were overweight or obese. While the majority  
28 of children were a healthy weight (65%), one in five was overweight or obese. Elevated BP (pre-  
29 hypertension or hypertension) was present in 88% of grandparents, 46% of parents, and 27% of  
30 children. In general, markers of cardiovascular disease risk worsened with age (**Table 1**), with 5% of  
31 children, 29% of parents, and 45% of grandparents categorised as having left ventricular hypertrophy.  
32  
33  
34  
35

### 36 *Results of random family and heritability analysis*

37  
38  
39 **Table 2** shows the results from comparing biological family pairs to randomly generated non-biological  
40 pairings, with statistically significant associations observed within families for cIMT between  
41 grandparents and parents, and for LVMI between all first-degree generations. Combining the  
42 heritability estimates from the different methods (**Table 3**) showed that heritability of cIMT ranged  
43 from 0.234 to 0.439 such that between 23% and 44% of the variation in cIMT was explained by  
44 heritability within families. For LVMI, the estimates from the various methods were closer, suggesting  
45 between 21% and 39% of the variation in LVMI was explained by heritability within families.  
46 Importantly, though the heritability estimates from the different estimation methods were related  
47 (**Suppl. figure 1**) and each parameter overlapped, high standard deviation for phylogenetic variance  
48 estimates as well as heritability estimates were observed.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Discussion

The aim of this study was to examine a range of phenotypic markers of cardiovascular risk across three generations to determine the degree to which these measures of vascular health are transmitted through generations in an urban South African family cohort, and give an indication of whether these findings in older generations can be used to trigger assessments of cardiovascular risk in younger generations. While we did not find significant heritability of blood pressure, possibly due to the high prevalence of elevated blood pressure and hypertension across all generations, our results do suggest that, in this population, structural markers of CV risk (intima media thickness in the common carotid artery (cIMT) and left ventricular mass (LVMI)) are heritable across African generations. This supports the intergenerational transmission of cardiovascular risk and identifies potential markers for the detection of at risk families.

To our knowledge, there is scant information to date on the degree to which these phenotypic markers of cardiovascular risk are heritable within African families. However, the heritability estimates we identified for these structural cardiovascular markers are similar to those reported in several previous studies from research outside of Africa. For example, our estimates for heritability of cIMT (23-44%) are similar to the 38% heritability reported in 586 families from the Framingham heart study<sup>19</sup> and the 34% reported in Latino parent-offspring pairs (69 families)<sup>50</sup>. However, our estimates are lower than the 56% heritability reported from 100 Dominican families in the Northern Manhattan study<sup>51</sup> and slightly higher than the 21% estimate reported in 32 American Indian families from the Strong Heart Family study<sup>17</sup>. Lower estimates may be related to the pedigrees included in the samples. For example, the Strong Heart Family study included first, second, third, fourth and greater degree relatives; while the other studies included only first degree relatives. Further studies in first-degree relatives from 76 families in France provide a similar cIMT heritability estimate of 30%<sup>52</sup>. Given our finding that significant heritability was observed in first-degree relatives (grandparent-parent) our results broadly agree with other studies and may be among the first to identify this heritability in families in Africa.

We also saw broad agreement between our heritability estimates for LVMI (21% to 39%) with estimates from studies outside of Africa including the Framingham heart study (30% heritability between parent-child pairs)<sup>22</sup>, from 52 White European families (23%), and from 368 Chinese families living in Taiwan (27%)<sup>21 53</sup>. Again, our estimate is higher than that from the Strong Heart Study (17%)<sup>54</sup> and lower than that from the Northern Manhattan study (49%)<sup>55</sup>. Our estimates are also lower than those from 169 hypertensive Japanese families living in Hawaii (43%)<sup>56</sup> and from the HyperGEN study (46%; 527 families, 51% African-America; 53% hypertensive)<sup>57</sup>. Generally, these higher heritability estimates for LVMI are from studies including or exclusively involving hypertensive participants.

1  
2  
3 However, this may not in itself explain the higher estimates as we included family members with  
4 hypertension, as did the GENOA study in African-American hypertensive siblings with 34% estimated  
5 heritability of LVMI<sup>24</sup>, falling within the range of our findings.  
6  
7

8  
9 When comparing our LVMI heritability estimates with the one study found within Africa (from 181  
10 nuclear families in our same urban township in South Africa)<sup>26</sup>, our estimates are lower. However, this  
11 study indexed LVM to height rather than BSA, with other studies showing this produces higher indexed  
12 LVMI values<sup>58</sup>. Importantly, the agreement between the studies that LVMI is heritable within families  
13 in this region supports the need for improved screening services.  
14  
15  
16

17  
18 Our findings for blood pressure were not expected and are contrary to other studies where blood  
19 pressure heritability has been observed within families. In a systematic review and meta-analysis by  
20 Kolifarhood et al. (2019), heritability of SBP and DBP was observed across regions ranging from 17-  
21 52% for SBP and 19-41% for DBP, though estimates were lower in African populations<sup>59</sup>. However,  
22 African data were scarce with one study in Nigeria from Adeyemo et al. (2002) reporting heritability  
23 estimates of 34% for SBP and 29% for DBP in 528 families including 1825 individuals<sup>60</sup>. While this was  
24 a large sample, heritability of BP has been observed in smaller African studies. For example, Bochud  
25 et al. (2005) found a significant heritability estimate for office SBP of 28% in 314 East African  
26 (Seychellois) adults from 76 families<sup>30</sup>. However, in this study family members were recruited for  
27 having at least two siblings with hypertension and family relationships included first degree (sibling  
28 pairs, parent-offspring pairs), second degree (grandparent-grandchild pairs, avuncular pairs i.e.  
29 uncle/aunt-niece/nephew) and third degree (first cousin pairs) relatives. Our research included only  
30 first and second degree relatives in whom heritability might be expected to be higher, though our  
31 overall sample size (n=198) was smaller.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

42 We also expected to find significant heritability for arterial stiffness within our families. Data from the  
43 Framingham Heart Study (1480 individuals from 817 families) suggests around 40% heritability of  
44 carotid-femoral pulse wave velocity<sup>20</sup>. While evidence from a study in Brazil (125 families, 1675  
45 individuals) shows a lower heritability estimate (27%)<sup>61</sup>, though this study also included first, second  
46 and third degree relatives. To our knowledge, our results may be some of the first to investigate the  
47 intergenerational heritability of carotid-femoral pulse wave velocity as a measure of arterial stiffness  
48 in families within South Africa and possibly, in Africa highlighting the need for further work in African  
49 families, perhaps increasing sample size through the inclusion of third-degree relatives.  
50  
51  
52  
53  
54

55  
56 Given constrained resources for cardiovascular disease treatment in the region, pragmatic and  
57 targeted prevention approaches are needed leveraging measurements that may be taken as part of  
58 routine clinical practice. Given the heritability of the factors identified in this study, we are not  
59  
60

1  
2  
3 suggesting that people should be screened for these factors to identify at risk children and families.  
4 Rather that offspring of adults in whom these factors are found should be targeted for rigorous  
5 assessment of risk, especially for raised LVM where this is measured in clinical practice.  
6  
7

### 8 9 *Strengths & Limitations*

10  
11 Our findings must be viewed in light of the limitations of this research, most notably the small sample  
12 size resulting in high standard deviations observed for phylogenetic variance estimates as well as  
13 heritability estimates. However, our heritability estimates from the different estimation methods for  
14 each parameter overlap giving confidence for our analysis, and the heritability estimates observed for  
15 CIMT and LVMI are similar to many of those reported previously. Additionally, the number of families  
16 included in this analysis is similar or more than many other heritability studies, with the random family  
17 method increasing the numbers of comparisons available. While our findings contribute to the small  
18 but growing evidence base for Africa, further research is needed across the continent to assess the  
19 generalisability of our results.  
20  
21  
22  
23  
24  
25

26  
27 A further limitation results from the individuals in which we could not collect all phenotypic markers  
28 of cardiovascular risk, most notably the SphygmoCor PWV and the echocardiography measures. This  
29 difficulty was in part due to excess body mass, for example the mean adult BMI of those with  
30 unsuccessful echocardiography measurement was  $40.9 \pm 10.5 \text{ kg/m}^2$ . Our lack of 24 hour ambulatory  
31 blood pressure monitoring (ABPM) data within families is also a limitation and future studies should  
32 consider the use of ABPM where feasible, as heritability estimates appear higher for ABPM than for  
33 office BP<sup>62</sup>. While we have successfully utilised ABPM in South African adults previously<sup>63</sup>, this was  
34 significantly more challenging in this urban cohort with young children and our attempts were not  
35 successful. Community-based support for families during ABPM measurement may be helpful in the  
36 future.  
37  
38  
39  
40  
41  
42  
43

44  
45 While it is noted that comparison with other studies can be problematic due to different populations,  
46 methods, study designs, and environmental influence on phenotypic variance as highlighted by North  
47 et al. (2002)<sup>17</sup>, we have taken care to compare our results only to studies that are methodologically  
48 similar. For example, all comparisons for LVMI heritability presented here include only studies using  
49 echocardiographic measurement of LVM, as LVM heritability estimates from electrocardiography may  
50 be higher<sup>23</sup>. Furthermore, heritability estimates for IMT often vary between the common carotid  
51 artery (CCA) and the internal carotid (ICA), with heritability estimates frequently higher for CCA, so  
52 that it is important to compare results for IMT measured in the same location.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 A key strength of this research is the contribution of evidence for the heritability and intergenerational  
4 transmission of cardiovascular health in African families, including children prior to adolescence, and  
5 the comparison of several different methods to estimate heritability. Further, the high levels of  
6 elevated blood pressure and hypertension observed in our population across older and younger adults  
7 and in the children reinforce the need for prevention programmes early in life.  
8  
9

## 10 11 12 **Conclusion**

13  
14 Our results suggest that structural cardiovascular indices in the common carotid artery and in the left  
15 ventricle of the heart are heritable within African families. Where adults are identified with elevated  
16 carotid intima media thickness or left ventricular hypertrophy, screening should be conducted in first  
17 and second-degree relatives, especially to identify younger individuals most at risk of later poor  
18 vascular health, where prevention efforts may yield the greatest returns. Better understanding of the  
19 factors that promote transmission of poor vascular health from one generation to the next will support  
20 development of interventions to break the upward spiral of CVD on the continent.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

31  
32 **Contributorship statement:** LJW, JD, SAN and IM conceived the idea for the manuscript and  
33 designed the analyses. IM and LJW performed the analyses. LJW, IM, JD, AKR, LS, SC, WS, SAN all  
34 contributed to the interpretation of the results. All authors contributed to drafting the manuscript  
35 and have seen and approved the final version. LJW is the guarantor for this work and accepts full  
36 responsibility for the work.  
37  
38  
39

40  
41 **Competing Interests:** JD is a member of the Trial Steering Committee for D-Clare (UK MRC funded  
42 study: MR/T023562/1) for which no payment is received. She is also a member of the DSMB for NIH  
43 funded study (5R01HL144708) for which an honoraria of \$200 is received. She has received the  
44 standard \$400 NIH honoraria for being a panel member of their Implementation Science Grant funding  
45 stream and is a member of the WHO working group to discern targets for the Diabetes Compact. No  
46 other competing interests are declared.  
47  
48  
49

50  
51 **Funding statement:** This work was supported by the Wellcome Trust (UK) grant number  
52 [214082/Z/18/Z].  
53  
54

55  
56 **Data sharing statement:** Data is available on request from SAN.  
57  
58  
59  
60



## References

1. World Health Organization - Noncommunicable Diseases (NCD) Country Profile; South Africa, 2018:[https://www.who.int/nmh/countries/zaf\\_en.pdf?ua=1](https://www.who.int/nmh/countries/zaf_en.pdf?ua=1).
2. United Nations - World Population Prospects: South Africa Life Expectancy 1950-2021:<https://www.macrotrends.net/countries/ZAF/south-africa/life-expectancy>.
3. National Department of Health, Statistics South Africa, South African Medical Research Council, ICF: South Africa Demographic and Health Survey 2016.
4. Owolabi M, Miranda JJ, Yaria J, et al. Controlling cardiovascular diseases in low and middle income countries by placing proof in pragmatism. *BMJ Global Health* 2016;1(3):e000105. doi: 10.1136/bmjgh-2016-000105
5. Sailam V, Karalis DG, Agarwal A, et al. Prevalence of emerging cardiovascular risk factors in younger individuals with a family history of premature coronary heart disease and low Framingham risk score. *Clinical Cardiology: An International Indexed and Peer-Reviewed Journal for Advances in the Treatment of Cardiovascular Disease* 2008;31(11):542-45.
6. Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. *Circulation* 2007;115(4):459-67.
7. Aznaouridis K, Dhawan SS, Quyyumi AA. Cardiovascular Risk Prediction by Measurement of Arterial Elastic Properties and Wall Thickness. *Advances in Vascular Medicine: Springer* 2009:399-421.
8. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. *Journal of the American College of Cardiology* 2010;55(13):1318-27.
9. Gosse P. Left ventricular hypertrophy as a predictor of cardiovascular risk. *Journal of hypertension* 2005;23:S27-S33.
10. Peters SA, Huxley RR, Woodward M. Comparison of the sex-specific associations between systolic blood pressure and the risk of cardiovascular disease: a systematic review and meta-analysis of 124 cohort studies, including 1.2 million individuals. *Stroke* 2013;44(9):2394-401.
11. Kagura J, Ong KK, Adair LS, et al. Paediatric hypertension in South Africa: An underestimated problem calling for action. *SAMJ: South African Medical Journal* 2018;108(9):708-09.
12. Hottenga J-J, Boomsma DI, Kupper N, et al. Heritability and stability of resting blood pressure. *Twin Research and Human Genetics* 2005;8(5):499-508.
13. Snieder H, Harshfield GA, Treiber FA. Heritability of blood pressure and hemodynamics in African-and European-American youth. *Hypertension* 2003;41(6):1196-201.
14. Kolifarhood G, Daneshpour M, Hadaegh F, et al. Heritability of blood pressure traits in diverse populations: a systematic review and meta-analysis. *Journal of human hypertension* 2019;33(11):775-85.
15. Djami-Tchatchou AT, Norton GR, Redelinguys M, et al. Intrafamilial aggregation and heritability of office- day blood pressure difference in a community of African ancestry: implications for genetic association studies. *Blood pressure monitoring* 2014;19(6):346-52.
16. Tarnoki AD, Tarnoki DL, Stazi MA, et al. Heritability of central blood pressure and arterial stiffness: a twin study. *J Hypertens* 2012;30(8):1564-71. doi: 10.1097/HJH.0b013e32835527ae [published Online First: 2012/06/13]
17. North KE, MacCluer JW, Devereux RB, et al. Heritability of carotid artery structure and function: the Strong Heart Family Study. *Arteriosclerosis, thrombosis, and vascular biology* 2002;22(10):1698-703.
18. Moskau S, Golla A, Grothe C, et al. Heritability of carotid artery atherosclerotic lesions: an ultrasound study in 154 families. *Stroke* 2005;36(1):5-8.

19. Fox CS, Polak JF, Chazaro I, et al. Genetic and environmental contributions to atherosclerosis phenotypes in men and women: heritability of carotid intima-media thickness in the Framingham Heart Study. *Stroke* 2003;34(2):397-401.
20. Mitchell GF, DeStefano AL, Larson MG, et al. Heritability and a genome-wide linkage scan for arterial stiffness, wave reflection, and mean arterial pressure: the Framingham Heart Study. *Circulation* 2005;112(2):194-99.
21. Jin Y, Kuznetsova T, Bochud M, et al. Heritability of left ventricular structure and function in Caucasian families. *European journal of echocardiography* 2011;12(4):326-32.
22. Post WS, Larson MG, Myers RH, et al. Heritability of left ventricular mass: the Framingham Heart Study. *Hypertension* 1997;30(5):1025-28.
23. Mayosi B, Keavney B, Kardos A, et al. Electrocardiographic measures of left ventricular hypertrophy show greater heritability than echocardiographic left ventricular mass. *European heart journal* 2002;23(24):1963-71.
24. Fox ER, Klos KL, Penman AD, et al. Heritability and genetic linkage of left ventricular mass, systolic and diastolic function in hypertensive African Americans (From the GENOA study). *American journal of hypertension* 2010;23(8):870-75.
25. Laurent S, Parati G. Heritability of arterial stiffness and central blood pressure: the Holy Grail for detecting patients at high cardiovascular risk? *Journal of Hypertension* 2012;30(8)
26. Peterson VR, Norton GR, Redelinghuys M, et al. Intrafamilial aggregation and heritability of left ventricular geometric remodeling is independent of cardiac mass in families of African ancestry. *American journal of hypertension* 2015;28(5):657-63.
27. Peterson VR, Norton GR, Libhaber CD, et al. Intrafamilial aggregation and heritability of tissue Doppler indexes of left ventricular diastolic function in a group of African descent. *Journal of the American Society of Hypertension* 2016;10(6):517-26. e11.
28. Richter LM, Norris SA, De Wet T. Transition from Birth to Ten to Birth to Twenty: the South African cohort reaches 13 years of age. *Paediatric and perinatal epidemiology* 2004;18(4):290-301.
29. Richter LM, Naicker SN, Norris SA. Birth to Twenty Plus: Early health and development from a longitudinal perspective. *Child and Adolescent Development: An expanded focus on public health in Africa* 2018:114.
30. Bochud M, Bovet P, Elston RC, et al. High heritability of ambulatory blood pressure in families of East African descent. *Hypertension* 2005;45(3):445-50.
31. Klein TW. Heritability and genetic correlation: statistical power, population comparisons, and sample size. *Behavior Genetics* 1974;4(2):171-89.
32. Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Bulletin of the World Health Organization* 2007;85:867-72.
33. Global Adult Tobacco Survey Collaborative Group. Tobacco Questions for Surveys: A Subset of Key Questions from the Global Adult Tobacco Survey (GATS), 2nd Edition. Atlanta, GA: Centers for Disease Control and Prevention, 2011.
34. Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG; The Alcohol Use Disorders Identification Test, Guidelines for Use in Primary Care, Second Edition, Department of Mental Health and Substance Dependence, World Health Organization, CH-1211 Geneva 27, Switzerland. ©World Health Organization 2001.
35. World Health Organization. Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, 8-11 December 2008. 2011
36. World Health Organization Physical status: The use of and interpretation of anthropometry, Report of a WHO Expert Committee: World Health Organization 1995.
37. Cole TJ, Bellizzi MC, Flegal KM, et al. Establishing a standard definition for child overweight and obesity worldwide: international survey. *Bmj* 2000;320(7244):1240.

- 1  
2  
3 38. Obe MA. Waist to height ratio and the Ashwell® shape chart could predict the health risks of  
4 obesity in adults and children in all ethnic groups. *Nutrition & Food Science* 2005  
5  
6 39. Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and  
7 management of high blood pressure in children and adolescents. *Pediatrics* 2017;140(3)  
8  
9 40. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular  
10 hypertrophy: comparison to necropsy findings. *The American journal of cardiology*  
11 1986;57(6):450-58.  
12  
13 41. Mosteller R. Simplified calculation of body-surface area. *The New England journal of medicine*  
14 1987;317(17):1098-98.  
15  
16 42. Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples). *Biometrika*  
17 1965;52(3/4):591-611.  
18  
19 43. Heß S. Randomization inference with Stata: A guide and software. *The Stata Journal*  
20 2017;17(3):630-51.  
21  
22 44. Usuzaki T, Chiba MSS, Hotta S. Random family method: Confirming inter-generational relations  
23 by restricted re-sampling. *arXiv preprint arXiv:200203467* 2020  
24  
25 45. Hadfield JD, Wilson AJ, Garant D, et al. The misuse of BLUP in ecology and evolution. *The*  
26 *American Naturalist* 2010;175(1):116-25.  
27  
28 46. Morrissey M, Kruuk L, Wilson AJ. The danger of applying the breeder's equation in observational  
29 studies of natural populations. *Journal of evolutionary biology* 2010;23(11):2277-88.  
30  
31 47. Zhao JH, Congdon P. Bayesian linear mixed models with polygenic effects. *Journal of Statistical*  
32 *Software* 2018;85(1):1-27.  
33  
34 48. Zhao J, Zhao H, Zhu L. Pivotal variable detection of the covariance matrix and its application to  
35 high-dimensional factor models. *Statistics and Computing* 2018;28(4):775-93.  
36  
37 49. Sinnwell JP, Therneau TM, Schaid DJ. The kinship2 R package for pedigree data. *Human heredity*  
38 2014;78(2):91-93.  
39  
40 50. Xiang AH, Azen SP, Buchanan TA, et al. Heritability of Subclinical Atherosclerosis in Latino  
41 Families Ascertained Through a Hypertensive Parent. *Arteriosclerosis, Thrombosis, and*  
42 *Vascular Biology* 2002;22(5):843-48. doi: doi:10.1161/01.ATV.0000015329.15481.E8  
43  
44 51. Sacco RL, Blanton SH, Slifer S, et al. Heritability and linkage analysis for carotid intima-media  
45 thickness: the family study of stroke risk and carotid atherosclerosis. *Stroke*  
46 2009;40(7):2307-12.  
47  
48 52. Zannad F, Visvikis S, Gueguen R, et al. Genetics strongly determines the wall thickness of the left  
49 and right carotid arteries. *Human genetics* 1998;103(2):183-88.  
50  
51 53. Chien K-L, Hsu H-C, Su T-C, et al. Heritability and major gene effects on left ventricular mass in  
52 the Chinese population: a family study. *BMC cardiovascular disorders* 2006;6(1):1-9.  
53  
54 54. Bella JN, MacCluer JW, Roman MJ, et al. Heritability of left ventricular dimensions and mass in  
55 American Indians: The Strong Heart Study. *Journal of hypertension* 2004;22(2):281-86.  
56  
57 55. Hank Juo S-H, Di Tullio MR, Lin H-F, et al. Heritability of left ventricular mass and other  
58 morphologic variables in Caribbean Hispanic subjects: the Northern Manhattan Family  
59 Study. *Journal of the American College of Cardiology* 2005;46(4):735-37.  
60  
61 56. Assimes TL, Narasimhan B, Seto TB, et al. Heritability of left ventricular mass in Japanese families  
62 living in Hawaii: the SAPPHERE Study. *Journal of hypertension* 2007;25(5):985-92.  
63  
64 57. De Simone G, Tang W, Devereux RB, et al. Assessment of the interaction of heritability of volume  
65 load and left ventricular mass: the HyperGEN offspring study. *Journal of hypertension*  
66 2007;25(7):1397-402.  
67  
68 58. Hense H-W, Gneiting B, Muscholl M, et al. The associations of body size and body composition  
69 with left ventricular mass: impacts for indexation in adults. *Journal of the American College*  
70 *of Cardiology* 1998;32(2):451-57. doi: doi:10.1016/S0735-1097(98)00240-X  
71  
72 59. Kolifarhood G, Daneshpour M, Hadaegh F, et al. Heritability of blood pressure traits in diverse  
73 populations: a systematic review and meta-analysis. *Journal of Human Hypertension*  
74 2019;33(11):775-85. doi: 10.1038/s41371-019-0253-4

- 1  
2  
3 60. Adeyemo AA, Omotade OO, Rotimi CN, et al. Heritability of blood pressure in Nigerian families.  
4 *Journal of Hypertension* 2002;20(5):859-63.  
5  
6 61. Alvim RO, Horimoto AR, Oliveira CM, et al. Heritability of arterial stiffness in a Brazilian  
7 population: Baependi Heart Study. *Journal of hypertension* 2017;35(1):105-10.  
8  
9 62. Fava C, Burri P, Almgren P, et al. Heritability of ambulatory and office blood pressure phenotypes  
10 in Swedish families. *Journal of hypertension* 2004;22(9):1717-21.  
11  
12 63. Ware LJ, Rennie KL, Gafane LF, et al. Masked hypertension in low-income South African adults.  
13 *The Journal of Clinical Hypertension* 2016;18(5):396-404.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**Table 1.** Characteristics of the n=65 included families (grandparents, parents and children)

	Grandparents n=65	Parents n=65	Children n=65
Age (years)	56 (10)	29 (0)	7 (3)
Female, n (%)	65 (100)	65 (100)	36 (55)
<i>Anthropometry</i>			
Height (cm)	157.3 (8.1)	159.5 (7.5)	122.5 (16.2)
Weight (Kg)	83.4 (25.9)	72.4 (22.7)	23.8 (9.3)
Mid-upper arm circumference (cm)	36.3 (7.4)	32.8 (8.7)	18.3 (4.4)
Waist circumference (cm)	104.4 (18.2)	88.1 (21.8)	54.8 (12.2)
Waist to height ratio	0.67 (0.12)	0.57 (0.15)	0.44 (0.07)
Body Mass Index (BMI, kg/m <sup>2</sup> )	34.5 (10.6)	29.3 (9.3)	15.7 (2.2)
Underweight, n (%)	1 (2)	1 (2)	9 (14)
Normal weight, n (%)	4 (6)	14 (21)	42 (65)
Overweight, n (%)	12 (18)	19 (29)	12 (19)
Obese, n (%)	48 (74)	31 (48)	2 (3)
<i>Medical history &amp; health behaviour</i>			
Previous diabetes diagnosis, n (%)	4 (6)	0	-
Previous hypertension diagnosis, n (%)	41 (63)	4 (6)	-
On antihypertensive medication, n (%)	40 (62)	2 (3)	-
Currently uses tobacco, n (%)	18 (28)	11 (17)	-
Harmful/hazardous alcohol use, n (%)	10 (15)	22 (34)	-
<i>Sphygmocor: Pulse wave analysis</i>			
	n=65	n=65	n=62
Brachial measures			
Systolic blood pressure (SBP, mmHg)	133 (28)	117 (18)	103 (11)
Diastolic blood pressure (DBP, mmHg)	80 (16)	73 (12)	63 (9)
Resting heart rate (bpm)	65 (15)	69 (12)	80 (14)
Blood pressure (BP) status, n (%)			
Normal/healthy BP	8 (12)	35 (54)	45 (73)
Elevated BP/Prehypertension	13 (20)	22 (34)	5 (8)
Hypertension	45 (68)	8 (12)	12 (19)
Central measures (c)			
cSBP (mmHg)	126 (26)	106 (16)	92 (12)
cDBP (mmHg)	81 (16)	74 (11)	64 (8)
Pulse pressure (mmHg)	42 (14)	33 (8)	28 (4)
Mean arterial pressure (mmHg)	99 (19)	87 (15)	79 (12)
<i>Sphygmocor: Pulse wave velocity</i>			
	n=57	n=61	n=56
Carotid-femoral PWV (m/s)	8.45 (1.83)	6.50 (0.88)	4.33 (0.64)
<i>Ultrasound Carotid Measurements</i>			
	n=63	n=63	n=63
Carotid IMT (cIMT left-side mm)	0.66 (0.18)	0.50 (0.10)	0.44 (0.09)
<i>Ultrasound Cardiac Measurements</i>			
	n=58	n=63	n=63
LVM indexed to body surface area (LVMI_BSA, g/m <sup>2</sup> )	91.4 (36.4)	82.8 (36.4)	56.4 (21.5)
Left ventricular hypertrophy, n (%)	26 (45)	18 (29)	3 (5)

Data are presented as median (IQR) unless otherwise indicated. For children, LVH was defined as LVMI >95th percentile (109.4 g/m<sup>2</sup>).

**Table 2.** Results of random family analysis.

Outcome	Exposure	Observed effect* [T(obs)]	c	n	P =c/n
Brachial SBP - GC	Brachial SBP - GP	0.029	3123	5000	0.625
Brachial SBP - GC	Brachial SBP - P	0.123	1027	5000	0.205
Brachial SBP - P	Brachial SBP - GP	0.109	967	5000	0.193
Brachial DBP - GC	Brachial DBP - GP	-0.006	4647	5000	0.929
Brachial DBP - GC	Brachial DBP - P	0.063	2676	5000	0.535
Brachial DBP - P	Brachial DBP - GP	0.001	4970	5000	0.994
Central SBP - GC	Central SBP - GP	-0.005	4649	5000	0.930
Central SBP - GC	Central SBP - P	0.075	2249	5000	0.450
Central SBP - P	Central SBP - GP	0.094	1392	5000	0.278
Central DBP - GC	Central DBP - GP	0.028	3379	5000	0.676
Central DBP - GC	Central DBP - P	0.119	1180	5000	0.236
Central DBP - P	Central DBP - GP	0.006	4702	5000	0.940
PWV - GC	PWV - GP	-0.006	4655	5000	0.931
PWV - GC	PWV - P	0.166	766	5000	0.153
PWV - P	PWV - GP	0.104	1038	5000	0.208
cIMT - GC	cIMT - GP	0.093	962	5000	0.192
cIMT - GC	cIMT - P	0.171	1445	5000	0.289
cIMT - P	cIMT - GP	0.133	83	5000	<b>0.017</b>
LVMI_BSA - GC	LVMI_BSA - GP	-0.076	2301	5000	0.460
LVMI_BSA - GC	LVMI_BSA - P	0.242	213	5000	<b>0.043</b>
LVMI_BSA - P	LVMI_BSA - GP	0.277	102	5000	<b>0.020</b>

GC- grandchild, P- parent, GP- grandparent, SBP – systolic blood pressure, DBP – diastolic blood pressure, cIMT – carotid intima media thickness, LVMI\_BSA – left ventricular mass indexed to body surface area. \*All exposure effects were adjusted for age, height, weight and sex in the regression models. P: the empirical probability value. C: the number of absolute effects  $\geq$  the observed targeted generation effect (e.g. grandparent on grandchild, grandparent on parent etc. as indicated by the formula below). n: the number of generated pseudo random families assessed on the targeted generation effect to determine c, where:  $c = \#\{|T| \geq |T(\text{obs})|\}$


**Table 3.** Heritability estimates from different methods

	cIMT (mm)			LVMI_BSA (g/m <sup>2</sup> )		
	ReML <sup>1</sup>	MCMC <sup>2</sup>	HMC <sup>3</sup>	ReML	MCMC	HMC
Phylogenetic variance (p)	0.131 (0.114)	0.310 (0.101)	0.175 (0.111)	0.180 (0.172)	0.405 (0.141)	0.240 (0.154)
Error variance	0.426 (0.070)	0.385 (0.056)	0.416 (0.065)	0.660 (0.107)	0.603 (0.085)	0.647 (0.095)
Phenotypic variance	0.556 (0.080)	0.695 (-)	0.591 (-)	0.840 (0.122)	1.008 (-)	0.887 (-)
Heritability ( $h^2$ )	0.234 (0.179)	0.439 (0.098)	0.282 (0.146)	0.214 (0.182)	0.394 (0.099)	0.258 (0.139)
$\beta^4$	0.709 (0.048)	0.705 (0.048)	0.708 (0.047)	0.496 (0.059)	0.496 (0.059)	0.493 (0.060)


<sup>1</sup>Restricted Maximum Likelihood, <sup>2</sup>Markov Chain Monte Carlo method, <sup>3</sup>Hamiltonian Monte Carlo method, <sup>4</sup>coefficient for age which was adjusted for in all models for both vascular markers

Supplementary figure 1 showing the relationships between the heritability parameters for LVMI (adjusted for body surface areas) and carotid IMT (cIMT).

**LVMI**



**cIMT**



### Appendix: Additional information on cardiovascular assessment methods

Arterial stiffness (carotid-femoral pulse wave velocity - PWV) was estimated, with tonometry of the carotid artery during inflation of an appropriate size femoral cuff. Pulse wave analysis (for central pressure estimation) and PWV measurement were set at 10 second intervals. Duplicate measures of PWV were taken and if the difference between PWV measures was  $\geq 0.5$  m/s, a third measure was taken and the average of two readings within 0.5m/s of each other used for analysis. All measures were taken on the right side with the participant resting supine for 10 minutes prior to measurement, and using the direct distance method to estimate aortic path length<sup>1</sup>. A total of 4 trained operators performed the PWV measurements after confirming inter-observer variability was acceptable ( $< 0.5$  m/s).

Left ventricular mass (LVM) was measured in 2D mode with transthoracic echocardiography following the American Society of Echocardiography (ASE) protocol<sup>2</sup>. The 2D mode has been shown to be superior to M-Mode for studies of LVM within families<sup>3</sup>. LV mass was assessed at end-diastole perpendicular to the long axis of the left ventricle. The Devereux formula was used to calculate LVM:  $LVM (g) = 0.8 \times 1.04 ((LVDd + IVSd + LVPWd)^3 - LVDd^3) + 0.6$  where LVDd=left ventricular diastolic diameter; IVSd= intraventricular septal diameter, LVPWd= left ventricular posterior wall thickness in diastole<sup>4</sup>.

Carotid intima-media thickness (cIMT) was determined using high resolution B-mode ultrasound employing a linear array 7.5 MHz probe as recommended<sup>5</sup>. Images of at least 1 cm length were obtained of the far wall of the distal portion of the left common carotid artery (CCA) from an optimal angle of incidence (defined as the longitudinal angle of approach where both branches of the internal and external carotid artery are visualised simultaneously). Semi-automated border detection and quality control software were used to calculate cIMT, with at least 3 measurements obtained from the left side and the mean used for analysis. Previous studies have reported no major differences between left and right CCA IMT in associations with cardiovascular disease<sup>6</sup>. All ultrasound measures were taken with the Mindray DC-70 Ultrasound system (Mindray, Shenzhen China).

1. Van Bortel LM, Laurent S, Boutouyrie P, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. *Journal of hypertension* 2012;30(3):445-48.



- 1
- 2
- 3
- 4 2. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by
- 5 echocardiography in adults: an update from the American Society of Echocardiography and the
- 6 European Association of Cardiovascular Imaging. *European Heart Journal-Cardiovascular*
- 7 *Imaging* 2015;16(3):233-71.
- 8 3. Shah SJ, Ober C, Lang RM. Two-Dimensional Echocardiography Is Superior to M-mode for the
- 9 Determination of Left Ventricular Mass: Evidence from a Heritability Study. *Journal of Cardiac*
- 10 *Failure* 2007;13(6):S155.
- 11 4. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular
- 12 hypertrophy: comparison to necropsy findings. *The American journal of cardiology*
- 13 1986;57(6):450-58.
- 14 5. Touboul P-J, Hennerici M, Meairs S, et al. Mannheim carotid intima-media thickness and plaque
- 15 consensus (2004–2006–2011). *Cerebrovascular diseases* 2012;34(4):290-96.
- 16 6. Bots ML, de Jong PT, Hofman A, et al. Left, right, near or far wall common carotid intima-media
- 17 thickness measurements: associations with cardiovascular disease and lower extremity arterial
- 18 atherosclerosis. *Journal of clinical epidemiology* 1997;50(7):801-07.
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

# Reporting checklist for cohort study.

Based on the STROBE cohort guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cohort reporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

	Reporting Item	Page Number
<b>Title and abstract</b>		
Title	<a href="#">#1a</a> Indicate the study's design with a commonly used term in the title or the abstract	1

1	Abstract	<a href="#">#1b</a>	Provide in the abstract an informative and	2
2				
3				
4			balanced summary of what was done and	
5				
6			what was found	
7				
8				
9	<b>Introduction</b>			
10				
11				
12	Background /	<a href="#">#2</a>	Explain the scientific background and	3
13				
14	rationale		rationale for the investigation being reported	
15				
16				
17	Objectives	<a href="#">#3</a>	State specific objectives, including any	4
18				
19			prespecified hypotheses	
20				
21				
22				
23	<b>Methods</b>			
24				
25				
26	Study design	<a href="#">#4</a>	Present key elements of study design early	4
27				
28			in the paper	
29				
30				
31	Setting	<a href="#">#5</a>	Describe the setting, locations, and relevant	4
32				
33			dates, including periods of recruitment,	
34				
35			exposure, follow-up, and data collection	
36				
37				
38				
39	Eligibility criteria	<a href="#">#6a</a>	Give the eligibility criteria, and the sources	4
40				
41			and methods of selection of participants.	
42				
43			Describe methods of follow-up.	
44				
45				
46	Eligibility criteria	<a href="#">#6b</a>	For matched studies, give matching criteria	n/a no matching
47				
48			and number of exposed and unexposed	
49				
50				
51				
52	Variables	<a href="#">#7</a>	Clearly define all outcomes, exposures,	5
53				
54			predictors, potential confounders, and effect	
55				
56				
57				
58				
59				
60				

1		modifiers. Give diagnostic criteria, if	
2		applicable	
3			
4			
5			
6	Data sources /	<a href="#">#8</a> For each variable of interest give sources of	5 & appendix
7	measurement	data and details of methods of assessment	
8		(measurement). Describe comparability of	
9		assessment methods if there is more than	
10		one group. Give information separately for	
11		for exposed and unexposed groups if	
12		applicable.	
13			
14			
15			
16			
17			
18			
19			
20			
21			
22	Bias	<a href="#">#9</a> Describe any efforts to address potential	5
23		sources of bias	
24			
25			
26			
27			
28	Study size	<a href="#">#10</a> Explain how the study size was arrived at	4
29			
30			
31	Quantitative	<a href="#">#11</a> Explain how quantitative variables were	5-8
32	variables	handled in the analyses. If applicable,	
33		describe which groupings were chosen, and	
34		why	
35			
36			
37			
38			
39			
40			
41	Statistical	<a href="#">#12a</a> Describe all statistical methods, including	5-8
42	methods	those used to control for confounding	
43			
44			
45			
46	Statistical	<a href="#">#12b</a> Describe any methods used to examine	5-8
47	methods	subgroups and interactions	
48			
49			
50			
51	Statistical	<a href="#">#12c</a> Explain how missing data were addressed	8
52	methods		
53			
54			
55			
56			
57			
58			
59			
60			

1	Statistical	<a href="#">#12d</a>	If applicable, explain how loss to follow-up	n/a no follow-up
2				
3	methods		was addressed	
4				
5				
6	Statistical	<a href="#">#12e</a>	Describe any sensitivity analyses	10 - Table 3 compares
7				
8	methods			three analysis methods
9				
10				
11				
12	<b>Results</b>			
13				
14				
15	Participants	<a href="#">#13a</a>	Report numbers of individuals at each stage	8
16				
17			of study—eg numbers potentially eligible,	
18			examined for eligibility, confirmed eligible,	
19			included in the study, completing follow-up,	
20			and analysed. Give information separately	
21			for for exposed and unexposed groups if	
22			applicable.	
23				
24				
25				
26				
27				
28				
29				
30				
31	Participants	<a href="#">#13b</a>	Give reasons for non-participation at each	8
32				
33			stage	
34				
35				
36				
37	Participants	<a href="#">#13c</a>	Consider use of a flow diagram	n/a – data in text, diagram
38				
39				not included at this stage
40				
41				
42				but can be added
43				
44				
45	Descriptive data	<a href="#">#14a</a>	Give characteristics of study participants (eg	9
46			demographic, clinical, social) and	
47			information on exposures and potential	
48			confounders. Give information separately for	
49			exposed and unexposed groups if	
50			applicable.	
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1	Descriptive data	<a href="#">#14b</a>	Indicate number of participants with missing	8-9
2				
3			data for each variable of interest	
4				
5				
6	Descriptive data	<a href="#">#14c</a>	Summarise follow-up time (eg, average and	n/a
7			total amount)	
8				
9				
10				
11	Outcome data	<a href="#">#15</a>	Report numbers of outcome events or	n/a
12				
13			summary measures over time. Give	
14			information separately for exposed and	
15			unexposed groups if applicable.	
16				
17				
18				
19				
20				
21				
22	Main results	<a href="#">#16a</a>	Give unadjusted estimates and, if applicable,	10-11, Table 2 and Table
23			confounder-adjusted estimates and their	3 - unadjusted estimates
24			precision (eg, 95% confidence interval).	can be provided for
25			Make clear which confounders were	regression analysis as a
26			adjusted for and why they were included	supplementary table if
27				required
28				
29				
30				
31				
32				
33				
34				
35				
36	Main results	<a href="#">#16b</a>	Report category boundaries when	9
37			continuous variables were categorized	
38				
39				
40				
41				
42	Main results	<a href="#">#16c</a>	If relevant, consider translating estimates of	n/a
43			relative risk into absolute risk for a	
44			meaningful time period	
45				
46				
47				
48				
49	Other analyses	<a href="#">#17</a>	Report other analyses done—eg analyses of	8-11
50			subgroups and interactions, and sensitivity	
51			analyses	
52				
53				
54				
55				
56				
57	<b>Discussion</b>			
58				
59				
60				

1	Key results	<a href="#">#18</a>	Summarise key results with reference to	11
2			study objectives	
3				
4				
5				
6	Limitations	<a href="#">#19</a>	Discuss limitations of the study, taking into	13
7			account sources of potential bias or	
8			imprecision. Discuss both direction and	
9			magnitude of any potential bias.	
10				
11	Interpretation	<a href="#">#20</a>	Give a cautious overall interpretation	11-14
12			considering objectives, limitations,	
13			multiplicity of analyses, results from similar	
14			studies, and other relevant evidence.	
15				
16	Generalisability	<a href="#">#21</a>	Discuss the generalisability (external	13
17			validity) of the study results	
18				
19				
20				
21				
22				
23				
24				
25				
26				
27				
28				
29				
30				
31				
32	<b>Other</b>			
33				
34	<b>Information</b>			
35				
36				
37	Funding	<a href="#">#22</a>	Give the source of funding and the role of	1
38			the funders for the present study and, if	
39			applicable, for the original study on which	
40			the present article is based	
41				
42				
43				
44				
45				
46				

## Notes:

- 6b: n/a no matching
- 8: 5 & appendix
- 12d: n/a no follow-up

- 1 • 12e: 10 - Table 3 compares three analysis methods  
2  
3  
4 • 13c: n/a - not included at this stage but can be added  
5  
6  
7 • 16a: 10-11, Table 2 and Table 3 - unadjusted estimates can be provided for regression analysis  
8  
9 as a supplementary table if required  
10  
11  
12  
13  
14

15 The STROBE checklist is distributed under the terms of the Creative Commons Attribution License  
16 CC-BY. This checklist was completed on 02. November 2021 using <https://www.goodreports.org/>, a  
17 tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



# BMJ Open

## Are cardiovascular health measures heritable across three generations of families in Soweto, South Africa? A cross-sectional analysis using the random family method.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-059910.R1
Article Type:	Original research
Date Submitted by the Author:	29-Jun-2022
Complete List of Authors:	<p>Ware, Lisa; University of the Witwatersrand, SAMRC Developmental Pathways for Health Research Unit; University of the Witwatersrand, DSI-NRF Centre of Excellence in Human Development Maposa, Innocent; University of the Witwatersrand Faculty of Health Sciences, Division of Epidemiology and Biostatistics, School of Public Health</p> <p>Kolkenbeck-ruh, Andrea; University of the Witwatersrand, SAMRC Developmental Pathways for Health Research Unit</p> <p>Norris, Shane; University of the Witwatersrand, SAMRC Developmental Pathways for Health Research Unit; University of Southampton, Global Health Research Institute, School of Human Development and Health &amp; NIHR Southampton Biomedical Research Centre</p> <p>Soepnel, Larske; University of the Witwatersrand, SAMRC Developmental Pathways for Health Research Unit; Julius Center for Health Sciences and Primary Care, Julius Global Health</p> <p>Crouch, Simone; University of the Witwatersrand, SAMRC Developmental Pathways for Health Research Unit</p> <p>Juliana, Kagura; University of the Witwatersrand Faculty of Health Sciences, Division of Epidemiology and Biostatistics, School of Public Health</p> <p>Naidoo, Sanushka ; University of the Witwatersrand, SAMRC Developmental Pathways for Health Research Unit</p> <p>Smith, Wayne; North-West University - Potchefstroom Campus, Hypertension in Africa Research Team (HART); SA MRC Unit for Hypertension and Cardiovascular Disease</p> <p>Davies, Justine ; University of Birmingham, Institute of Applied Health Sciences; Stellenbosch Institute for Advanced Study, Wallenberg Research Centre at Stellenbosch University</p>
<b>Primary Subject Heading</b>:	Cardiovascular medicine
Secondary Subject Heading:	Public health, Global health
Keywords:	Hypertension < CARDIOLOGY, CLINICAL PHYSIOLOGY, PREVENTIVE MEDICINE, PUBLIC HEALTH, Cardiovascular imaging < RADIOLOGY & IMAGING

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 1 **Are cardiovascular health measures heritable across three generations of families in Soweto, South**  
4 **Africa? A cross-sectional analysis using the random family method.**

5 2  
6  
7 3 Lisa J Ware<sup>1,2</sup>, Innocent Maposa<sup>3</sup>, Andrea Kolkenbeck-Ruh<sup>1</sup>, Shane A Norris<sup>1, 2</sup>, Larske Soepnel<sup>1, 4</sup>,  
8 4 Simone Crouch<sup>1</sup>, Juliana Kagura<sup>3</sup>, Sanushka Naidoo<sup>1</sup>, Wayne Smith<sup>5</sup>, Justine Davies<sup>6</sup>.

9 5  
10  
11  
12  
13 6 <sup>1</sup>SAMRC/Wits Developmental Pathways for Health Research Unit, Faculty of Health Sciences,  
14 7 University of the Witwatersrand, Johannesburg 2000, South Africa.

15 8 <sup>2</sup>DSI-NRF Centre of Excellence in Human Development, University of the Witwatersrand,  
16 9 Johannesburg 2000, South Africa.

17 10 <sup>3</sup>Division of Epidemiology and Biostatistics, School of Public Health, Faculty of Health Sciences,  
18 11 University of the Witwatersrand, Johannesburg, 2000, South Africa

19 12 <sup>4</sup>Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center  
20 13 Utrecht, Utrecht University, Utrecht, The Netherlands.

21 14 <sup>5</sup>Hypertension in Africa Research Team (HART), North-West University, South Africa. South African  
22 15 Medical Research Council: Unit for Hypertension and Cardiovascular Disease, North-West University,  
23 16 South Africa.

24 17 <sup>6</sup>Stellenbosch Institute for Advanced Study, Wallenberg Research Centre at Stellenbosch University,  
25 18 Stellenbosch 7600, South Africa; MRC/Wits Rural Public Health and Health Transitions Research Unit,  
26 19 School of Public Health, University of the Witwatersrand, Johannesburg, South Africa; Institute of  
27 20 Applied Health Sciences, University of Birmingham, Birmingham, UK

28 21  
29  
30  
31  
32  
33  
34  
35  
36  
37 22 Running title: Vascular health heritability in South African families.

38  
39 23 Word count: 4236 excluding abstract and references

40 24 Number of tables: 3

41 25 Number of figures: 0

42 26 Number of supplementary digital content: 1

43 27  
44 28 Correspondence: Lisa Ware, SAMRC/Wits Developmental Pathways for Health Research Unit, Faculty  
45 29 of Health Sciences, University of the Witwatersrand, Chris Hani Baragwanath Academic Hospital, 26  
46 30 Chris Hani Road Soweto Johannesburg, South Africa. Tel: +27 (0)10 447 3721, email  
47 31 lisa.ware@wits.ac.za

48 32

49 33

50 34

51 35

52 36

53 37

54 38

55 39

56 40

57 41

58  
59  
60

## 1 **Abstract**

2 Objectives: Cardiovascular disease is increasing in many low-middle income countries, including those  
3 in Africa. To inform strategies for the prevention of cardiovascular disease in South Africa, we sought  
4 to determine the broad heritability of phenotypic markers of cardiovascular risk across three  
5 generations.

6 Design: A cross-sectional study conducted in a longitudinal family cohort.

7 Setting: Research unit within a tertiary hospital in a historically disadvantaged, large urban township  
8 of South Africa.

9 Participants: 195 individuals from 65 biological families with all three generations including third  
10 generation children aged 4-10 years were recruited from the longest running intergenerational cohort  
11 study in Africa, the Birth to Twenty Plus cohort. All adults (grandparents and parents) were female,  
12 while children were male or female.

13 Primary and secondary outcome measures: The primary outcome was heritability of blood pressure  
14 (BP, brachial and central pressures). Secondary outcomes were heritability of arterial stiffness (pulse  
15 wave velocity), carotid intima media thickness (cIMT), and left ventricular mass indexed to body  
16 surface area (LVMI).

17 Results: While no significant intergenerational relationships of BP or arterial stiffness were found,  
18 there were significant relationships in LVMI across all three generations ( $p < 0.04$ ), and in cIMT between  
19 grandparents and parents ( $p = 0.0166$ ). Heritability, the proportion of phenotypic trait variation  
20 attributable to genetics, was estimated from three common statistical methods and ranged from 23  
21 to 44% for cIMT and from 21 to 39% for LVMI.

22 Conclusions: Structural indicators of vascular health, which are strong markers of future clinical  
23 cardiovascular outcomes transmit between generations within African families. Identification of these  
24 markers in parents may be useful to trigger assessments of preventable risk factors for cardiovascular  
25 disease in offspring.

26 **Keywords:** Vascular diseases, pulse wave analysis, heart disease, family, South Africa

### 27 **Strengths:**

- 28 • Intergenerational transmission was evaluated for a range of indicators of cardiovascular
- 29 health within urban African families
- 30 • The sample included biological family members from three generations

- 1
- 2
- 3 1 • Heritability estimates were compared for three commonly used statistical methods.
- 4
- 5

6 2 **Limitations:**

7

- 8 3 • The sample size is a limitation with the random family statistical method used to increase the
- 9 numbers of comparisons available.
- 10 4
- 11 5 • Only maternal family members were included.
- 12
- 13
- 14 6

15

16 7 **Introduction**

17

18 8 Within South Africa, a quarter of all adults are hypertensive and one in five deaths are from

19 cardiovascular disease (CVD)[1]. CVD mortality and morbidity are set to rise with increasing life

20 9 expectancy (now at 64 years; an increase of 10% in the last decade)[2], and increasing levels of

21 10 overweight and obesity (68% women, 31% men)[3]. Much focus is placed on detecting and treating

22 11 CVD, but with limited healthcare resources, pragmatic approaches are needed including primary

23 12 prevention in younger, at-risk individuals to prevent CVD[4].

24 13

25 14 Estimation of heritability or the proportion of variation in a phenotypic trait between individuals that

26 15 is attributable to genetic factors, has been used for many years to predict disease risk in medicine[5].

27 16 While there may be debate regarding the exact measurement of genetic, environmental and

28 17 interaction effects on trait variability, broadly heritability indicates the degree of resemblance of a

29 18 trait within biological families[6]. There is evidence that strong predictors of future adverse

30 19 cardiovascular outcomes (such as heart attacks and strokes) may be transmitted through biological

31 20 families so that measures in parents or grandparents may identify children at future risk[7].

32

33 21 Early vascular predictors of CVD outcomes include both structural (e.g. thickening or stiffening of

34 22 arterial walls, cardiac hypertrophy) and functional changes (e.g. elevated blood pressure)[8-12].

35 23 Hypertension is the largest contributor to CVD in Africa, with research showing elevated blood

36 24 pressure in children as young as 5 years of age[13]. Studies of mono- and dizygotic twins have shown

37 25 high heritability of systolic and diastolic blood pressure in populations of both African and European

38 26 descent[14, 15], though heritability may be lower for individuals of African descent[16]. Within South

39 27 Africa, data is also emerging that blood pressure is heritable across families (parent-child, and sibling

40 28 pairs)[17]. However, due to the high levels of hypertension in South African adults, hypertension in a

41 29 family member is unlikely on its own to be a sensitive enough indicator to identify at risk young adults

42 30 or children for intervention.

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

1  
2  
3 1 As such, additional measures may be needed to identify those family members most at risk and where  
4  
5 2 early intervention may have greater returns. Evidence from outside of Africa has shown that several  
6  
7 3 other markers of cardiovascular disease risk are heritable. For example, central blood pressures may  
8  
9 4 show stronger heritability than the brachial blood pressures typically measured in routine care[18].  
10  
11 5 Also carotid artery structure, function and pathology have been shown as heritable, with diameter  
12  
13 6 and carotid intima media thickness appearing as the most heritable traits.[19-21] Furthermore arterial  
14  
15 7 stiffness, as assessed by pulse wave velocity, has also been reported as heritable within family  
16  
17 8 studies[18, 22] and findings from echocardiography studies suggest that several cardiac measurement  
18  
19 9 parameters may be heritable within families, including left ventricular (LV) function and structure  
20  
21 10 including LV mass and LV hypertrophy[23-26]. Indeed, the combination of arterial stiffness and central  
22  
23 11 pressure has been suggested as a potential tool to investigate risk in nuclear families[27].

24  
25 12 However, there is limited evidence from African families to indicate which indicators of cardiovascular  
26  
27 13 health are most related and therefore, potentially most useful to indicate intergenerational risk within  
28  
29 14 family units in South Africa. One previous study suggested that echocardiography may be particularly  
30  
31 15 useful to detect intergenerational transmission of changes in cardiac structure and function in South  
32  
33 16 African families (parent-child, sibling-sibling pairs)[28, 29], though how this and other vascular  
34  
35 17 measures are related across children, parents and grandparents in the region is not known.  
36  
37 18 Additionally, the frequent background of undernutrition and burden of infectious diseases may mean  
38  
39 19 that heritability estimates are different in Africa to elsewhere.

40  
41 20 Therefore, we sought to investigate how a range of indicators of cardiovascular health (brachial and  
42  
43 21 central pressures, arterial stiffness, carotid intima media thickness and echocardiography findings)  
44  
45 22 were related within three generations (grandparents, parents and children) of African families from  
46  
47 23 urban South Africa to inform further risk identification and potential targeted CVD prevention efforts.

## 48 24 **Methods**

### 49 25 *Study population and sample size*

50  
51 26 Biological families with three generations (grandmother, mother and child [boy or girl age 4-10 years])  
52  
53 27 were recruited from the largest and longest running birth cohort study in Africa; the Birth to Twenty  
54  
55 28 Plus (Bt20-plus) cohort described in detail previously[30, 31]. Families in this cohort are tracked over  
56  
57 29 time through engagement in ongoing assessments. In 2019, a database of 162 Bt20-plus index children  
58  
59 30 (now the mothers) was drawn from all previous Birth to Twenty assessments that indicated both  
60  
31 survival of their biological mother and birth of a biological child. These index children were then  
32 contacted by telephone to confirm the presence of their biological mother, and a biological child

1  
2  
3 1 between the ages of 4 and 9 years. Families with participants who were pregnant, experiencing  
4 2 current acute illness, or with any major congenital disorders were excluded. All eligible families were  
5 3 invited to take part. The study design was a cross-sectional in-depth assessment of vascular health at  
6 4 a research unit located within the grounds but operating independently of the outpatient and  
7 5 inpatient services of a large tertiary government hospital in Soweto, a historically disadvantaged  
8 6 township in South Africa. Data was collected between August 2019 and March 2020. Previous work in  
9 7 East African families found high heritability of blood pressure (systolic, diastolic and pulse pressure  $h^2$   
10 8 0.37, 0.24, 0.54), though the authors did not assess other vascular measures[32]. Based on these  
11 9 previous reported levels of heritability between two generations and using the methods of Klein et  
12 10 al.[33],  $n=65$  families ( $n=195$  individuals) at  $\alpha=0.05$ , would give 82% power to detect an  $h^2$  of 0.4,  
13 11 and 94% power to detect an  $h^2$  of 0.5 in blood pressure. With three generations, these estimates may  
14 12 be conservative.

### 13 *Ethical considerations*

14 14 Trained researchers who spoke the participant's home language explained the study and all  
15 15 participants provided written informed consent prior to taking part in the study. For children, the  
16 16 mother of the child provided written consent, with children age 7 years and above also giving their  
17 17 written assent to take part. The Human Research Ethics Committee (Medical) of the University of the  
18 18 Witwatersrand approved the protocol (Ref: M190263). We used the STROBE cohort checklist when  
19 19 writing our report[34].

### 20 *Patient and Public Involvement*

21 21 The study design was informed by previous work with two generations from this cohort, where  
22 22 participants expressed a desire to include additional generations in cardiovascular health  
23 23 assessments. However, participants were not involved in the study design, recruitment or conduct of  
24 24 the study. During 2022, a series of workshops are planned with the community to disseminate results  
25 25 and to explore the co-creation of potential community level interventions.

### 26 *Measurements*

27 27 Standard protocols were used for collection of all data, with the same staff repeating all measures or  
28 28 assessments of inter-operator variability conducted as described further in the appendix. Medical  
29 29 history (including antihypertensive medication use) and health behaviours were recorded via self-  
30 30 report. Tobacco use (daily or occasional current use of both smoked and smokeless tobacco products)  
31 31 was assessed using questions from the Global Adult and Tobacco Survey[35]. Alcohol use was  
32 32 evaluated using the World Health Organization Alcohol Use Disorders Identification Test (WHO-



1  
2  
3 1 AUDIT)[36], with hazardous or harmful alcohol use assessed as an AUDIT-C score (first three questions  
4 – shortened form) of  $\geq 3$  and/or a total AUDIT score of  $\geq 8$ .

5  
6  
7 3 Trained researchers measured height and weight in triplicate to the nearest 0.1cm and 0.1kg using a  
8 portable stadiometer and electronic scale (SECA, Hamburg, Germany). Waist and mid-upper arm  
9 circumference (MUAC) were measured in triplicate to the nearest 0.1cm following standard  
10 measurement protocols[37, 38].

11  
12  
13 7 All measures were taken in the morning following an overnight fast and with no caffeine or tobacco  
14 for at least 3 hours prior to measurement. Using the Sphygmocor Excel device (AtCor Medical,  
15 Naperville, USA) with appropriate size brachial cuff, brachial blood pressure and resting heart rate  
16 were determined, and central arterial pressures (cSBP, cDBP, pulse and mean arterial pressure) were  
17 estimated. Three measurements were taken, with the second and third measures averaged for  
18 analysis. Ultrasound measures were taken in triplicate with the Mindray DC-70 Ultrasound system  
19 (Mindray, Shenzhen China). Further detail for these assessments is provided in the appendix.

#### 20 21 22 23 24 25 26 27 14 *Analyses*

28  
29  
30 15 The primary outcome was heritability of blood pressure (BP, brachial and central pressures).  
31 Secondary outcomes were heritability of arterial stiffness (pulse wave velocity), carotid intima media  
32 thickness (cIMT), and left ventricular mass indexed to body surface area (LVMI). All exposure effects  
33 were adjusted for age, height, weight and sex in the regression models, with heritability estimates  
34 adjusted for age.

35  
36  
37  
38 20 For adults, body mass index (BMI kg/height m<sup>2</sup>) was categorised as follows: <18.5 underweight; 18.5-  
39 24.9 normal weight; 25.0-29.9 overweight;  $\geq 30$  obese. Children's BMI was categorised as underweight,  
40 normal, overweight or obese using age- and sex-specific cut-offs from the International Obesity Task  
41 Force (IOTF)[39]. Waist to height ratio was calculated for both adults and children, as this has  
42 previously been shown as a predictor of health risks of obesity across the lifecourse in all ethnic  
43 groups[40]. In adults, prehypertension was defined as 120-139 mmHg systolic or 80-89 mmHg diastolic  
44 and not currently taking antihypertensive medication, while hypertension was defined as a blood  
45 pressure  $\geq 140$  mmHg systolic or  $\geq 90$  mmHg diastolic or currently taking antihypertensive medication.  
46  
47 25 For children, elevated blood pressure was defined using the age, sex, and height adjusted percentiles  
48 of the American Academy of Pediatrics Clinical Practice Guideline (2017)[41].

49  
50  
51  
52 30 The Devereux formula was used to calculate LVM[42] and left ventricular mass index (LVMI) was  
53 calculated as a ratio of LVM indexed to body surface area[43]. Left ventricular hypertrophy (LVH) was  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 1 defined as LVMI>95g/m<sup>2</sup> for adult women and LVMI >95th percentile for children. Normality of data  
4  
5 2 were checked with visual inspection of histograms and the Shapiro-Wilk test[44].  
6

7 3 Our analyses followed two stages. Stage 1) determining the association between parent-offspring  
8  
9 4 pairs for each of the vascular health traits, and stage 2) estimating heritability for traits that exhibited  
10  
11 5 an association in the parent-offspring pairs. Participant characteristics and the associated vascular  
12  
13 6 health measurements are also described.

#### 14 7 *Stage 1. Random family method*

15  
16  
17 8 In this study we used the random family method as described in detail by Usuzaki et al. (2020) and  
18  
19 9 implemented the analysis based on Heß (2017) randomization inference algorithm[45, 46]. We used  
20  
21 10 resampling of the exposure variable to generate the distribution of parental trait effect on offspring,  
22  
23 11 controlling for confounding variables as below. We used the classical model generally used to explore  
24  
25 12 heritability in phenotypic traits:

$$26 13 \quad y_i = \beta_0 + \tau z_i + \beta X + \epsilon_i$$

27  
28 14 where  $y_i$  is the offspring trait,  $\tau$  is the “treatment” effect (regression slope) for  $z_i$ , the parental  
29  
30 15 trait.  $X$  is a matrix of control variables and  $\beta$  the associated coefficients.  $\tau$  is obtained for the original  
31  
32 16 pairs  $(z_i, y_i)$  and using randomization inference tests, we performed 5000 resampling-based pairs to  
33  
34 17 obtain the distribution of the statistic  $\tau$ , that is, the distribution of random parental trait effect on  
35  
36 18 offspring’s corresponding trait. Randomization inference tests have the advantage that they can  
37  
38 19 handle small sample sizes and do not rely on validity of the specified model regardless of the  
39  
40 20 generated statistic being from the model[45]. Randomization inference also produces the distribution  
41  
42 21 of a test statistic under a designated null hypothesis, thereby allowing us to assess whether the  
43  
44 22 observed (original parent-offspring pair) relationship statistic (regression coefficient) is significantly  
45  
46 23 different and hence the null hypothesis can be rejected in favor of the parental trait having a  
47  
48 24 significant influence on the offspring trait. In brief, regression coefficients were generated for all  
49  
50 25 primary and secondary cardiovascular measures within the biological families: adjusting brachial and  
51  
52 26 central pressures, pulse wave velocity and cIMT for age, height, weight and sex; and adjusting LVMI  
53  
54 27 for age and sex only as it is already indexed to body surface area. Restricted resampling of the data  
55  
56 28 was then employed to generate 5000 random family units ensuring random pairing of parent off-  
57  
58 29 spring biological families. The regression coefficients for each cardiovascular outcome marker were  
59  
60 30 then compared between the family pair and random pairs. Kernel density plots of  $\tau$ -values for original  
31  
32 31 family pairs and random pair  $\tau$ - values were then generated to assess statistical significance of the  
selected traits.

## 1 Stage 2. Heritability Estimation

2 For those variables which showed significantly greater association between family members  
 3 compared with randomly generated pairs using the random family method, heritability estimate(s)  
 4 were derived using the variance components decomposition method based on the linear mixed effects  
 5 model (LMM) as all vascular health traits of interest were continuous. The Restricted Maximum  
 6 Likelihood (ReML) method was used to estimate the variance components and hence heritability.  
 7 However, due to concerns by Hadfield (2010) and Morrissey (2010) on ReML limitations[47, 48], we  
 8 additionally implemented the Bayesian method for variance components and heritability  
 9 estimation[49], thereby creating a range for each heritability estimate. The basic model (LMM) is:

$$10 \quad Y|Z,X \sim N(X\beta, G\sigma_g^2 + I\sigma_e^2)$$

11 where additive genetic variance of the trait  $G$  is estimated using relatedness information  
 12 between individuals or genotypes  $Z$  with both fixed effects  $\beta$  for  $X$  control variables,  $\epsilon_i \sim N(0, \sigma_e^2)$  and  
 13 random effects following a normal distribution with mean 0 and variance  $G\sigma_g^2$  [50].  $G$  is the genetic  
 14 relatedness matrix (GRM) and was estimated using the kinship package in R (R version 4.0.2)[51]. We  
 15 also used the kinship package to plot the pedigree of one family in our dataset. The Bayesian linear  
 16 mixed model with polygenic effects ( $g$ ) having the following sampling model:

$$17 \quad y|\beta, u, \sigma^2 \sim N(X\beta + Zu, \sigma^2 I), \quad \beta \sim N(0, \sigma_\beta^2 B), \quad u \sim N(0, \sigma^2 G)$$

18 where  $B$  is known and non-singular diagonal matrix and  $\sigma_\beta^2$  as a hyperparameter was used.  
 19 The  $G$  in  $\sigma^2 G$  is the genetic relatedness matrix estimated through the kinship package for the family  
 20 relatedness. Note, for this model the likelihood and assumed priors were:

$$21 \quad y_i \sim N(\mu, \sigma^2 I)$$

$$22 \quad \mu = X\beta + g$$

$$23 \quad \beta_j \sim N(0, 1000^2), \quad \forall j = 1, \dots, p$$

$$24 \quad g \sim N(0, \sigma_g^2 G)$$

$$25 \quad \sigma_g^2 \sim \text{InvGamma}(s_1, s_2)$$

$$26 \quad \sigma^2 \sim \text{InvGamma}(s_1, s_2)$$

27 where  $s_1$  and  $s_2$  are chosen to provide noninformative priors. We used rJAGS and rSTAN to  
 28 perform markov chain monte carlo (MCMC) and hamiltonian monte carlo (HMC) simulations

1  
2  
3  
4 1 respectively[50]. Heritability was then computed as  $h^2 = \frac{\sigma_g^2}{\sigma_g^2 + \sigma^2}$ . The marginal distributions of all  
5  
6 2 parameters and estimation of the best linear unbiased predictions (BLUP) for the model were obtained  
7  
8 3 using Gibbs' sampling (MCMC) and the leapfrog integration method (HMC). The samplers made  
9  
10 4 100000 simulations and only results of the last 90000 were used in the inference. We used two  
11  
12 5 Bayesian paradigms to enable comparisons and manage the inherent uncertainty associated with  
13  
14 6 estimating genetic variance components[47] as well as in using small sample sizes. Age of the  
15  
16 7 participant was used as a control variable for all models and was standardized together with the  
17  
18 8 vascular health traits before estimation to improve efficiency of Bayesian sampling.

## 9 **Results**

10 Of the 162 index children identified: n=48 (30%) could not be contacted either as the telephone  
11  
12 11 number had changed or they did not respond to calls or voice messages; n=14 (9%) did not wish to  
13  
14 12 take part; n=5 (3%) were not eligible due to current illness, pregnancy, or a biological child not in the  
15  
16 13 required age range; n=4 (2%) were no longer residing in Soweto; n=3 (2%) were not available due to  
17  
18 14 school or work commitments; and n=9 (6%) booked appointments but did not attend. Finally, 65  
19  
20 15 families (49% of those contacted) took part in the study providing n=130 adults and n=65 children and  
21  
22 16 generating 195 biological pairings: 130 first generation and 65 second generation.

23  
24 17 Whole family completion rates for the vascular measures were as follows: carotid ultrasound (n=63);  
25  
26 18 brachial blood pressure, heart rate and pulse wave analysis (n=62); echocardiography (n=59); PWV  
27  
28 19 (n=40); all vascular measures (n=40). Families with complete anthropometry data and at least one  
29  
30 20 vascular measurement complete for a family pairing (parent/child, grandparent/parent or  
31  
32 21 grandparent/grandchild) were included in the analysis as the random family method does not require  
33  
34 22 all three generations to have data, only that a family has one or more biological pairs with valid  
35  
36 23 measurements. Descriptive characteristics are presented in Table 1, including the number of adults  
37  
38 24 and children with successful measurements for each variable.

39  
40 25 Median age of grandparents, parents and children was 56 years, 29 years and 7 years respectively. All  
41  
42 26 parents and grandparents were female, while 45% of children were male. Among adults, 92% of  
43  
44 27 grandparents and 77% of parents were overweight or obese. While the majority of children were a  
45  
46 28 healthy weight (65%), one in five was overweight or obese. Elevated BP (pre-hypertension or  
47  
48 29 hypertension) was present in 88% of grandparents, 46% of parents, and 27% of children. In general,  
49  
50 30 markers of cardiovascular disease risk worsened with age (**Table 1**), with 5% of children, 29% of  
51  
52 31 parents, and 45% of grandparents categorised as having left ventricular hypertrophy.

53  
54  
55  
56  
57  
58  
59  
60 32 *Results of random family and heritability analysis*

**Table 2** shows the results from comparing biological family pairs to randomly generated non-biological pairings, with statistically significant associations observed within families for cIMT between grandparents and parents, and for LVMI between all first-degree generations. Combining the heritability estimates from the different methods (**Table 3**) showed that heritability of cIMT ranged from 0.234 to 0.439 such that between 23% and 44% of the variation in cIMT was explained by heritability within families. For LVMI, the estimates from the various methods were closer, suggesting between 21% and 39% of the variation in LVMI was explained by heritability within families. Importantly, though the heritability estimates from the different estimation methods were related (**Suppl. figure 1**) and each parameter overlapped, high standard deviation for phylogenetic variance estimates as well as heritability estimates were observed.

## Discussion

The aim of this study was to examine a range of phenotypic markers of cardiovascular risk across three generations to determine the degree to which these measures of vascular health are transmitted through generations in an urban South African family cohort, and give an indication of whether these findings in older generations can be used to trigger assessments of cardiovascular risk in younger generations. While we did not find significant heritability of blood pressure, possibly due to the high prevalence of elevated blood pressure and hypertension across all generations, our results do suggest that, in this population, structural markers of CV risk (intima media thickness in the common carotid artery (cIMT) and left ventricular mass (LVMI)) are heritable across African generations. This supports the intergenerational transmission of cardiovascular risk and identifies potential markers for the detection of at risk families.

To our knowledge, there is scant information to date on the degree to which these phenotypic markers of cardiovascular risk are heritable within African families. However, the heritability estimates we identified for these structural cardiovascular markers are similar to those reported in several previous studies from research outside of Africa. For example, our estimates for heritability of cIMT (23-44%) are similar to the 38% heritability reported in 586 families from the Framingham heart study[21] and the 34% reported in Latino parent-offspring pairs (69 families)[52]. However, our estimates are lower than the 56% heritability reported from 100 Dominican families in the Northern Manhattan study[53] and slightly higher than the 21% estimate reported in 32 American Indian families from the Strong Heart Family study[19]. Lower estimates may be related to the pedigrees included in the samples. For

1  
2  
3 1 example, the Strong Heart Family study included first, second, third, fourth and greater degree  
4 2 relatives, while the other studies included only first degree relatives. Further studies in first-degree  
5 3 relatives from 76 families in France provide a similar cIMT heritability estimate of 30%[54]. Given our  
6 4 finding that significant heritability was observed in first-degree relatives (grandparent-parent) our  
7 5 results broadly agree with other studies and may be among the first to identify this heritability in  
8 6 families in Africa.

9  
10 7 We also saw broad agreement between our heritability estimates for LVMI (21% to 39%) with  
11 8 estimates from studies outside of Africa including the Framingham heart study (30% heritability  
12 9 between parent-child pairs)[24], from 52 White European families (23%), and from 368 Chinese  
13 10 families living in Taiwan (27%)[23, 55]. Again, our estimate is higher than that from the Strong Heart  
14 11 Study (17%)[56] and lower than that from the Northern Manhattan study (49%)[57]. Our estimates  
15 12 are also lower than those from 169 hypertensive Japanese families living in Hawaii (43%)[58] and from  
16 13 the HyperGEN study (46%; 527 families, 51% African-America; 53% hypertensive)[59]. Generally, these  
17 14 higher heritability estimates for LVMI are from studies including or exclusively involving hypertensive  
18 15 participants. However, this may not in itself explain the higher estimates as we included family  
19 16 members with hypertension, as did the GENOA study in African-American hypertensive siblings with  
20 17 34% estimated heritability of LVMI[26], falling within the range of our findings.

21  
22 18 When comparing our LVMI heritability estimates with the one study found within Africa (from 181  
23 19 nuclear families in our same urban township in South Africa)[28], our estimates are lower. However,  
24 20 this study indexed LVM to height rather than BSA, with other studies showing this produces higher  
25 21 indexed LVMI values[60]. Importantly, the agreement between the studies that LVMI is heritable  
26 22 within families in this region supports the need for improved screening services.

27  
28 23 Our findings for blood pressure were not expected and are contrary to other studies where blood  
29 24 pressure heritability has been observed within families. In a systematic review and meta-analysis by  
30 25 Kolifarhood et al. (2019), heritability of SBP and DBP was observed across regions ranging from 17-  
31 26 52% for SBP and 19-41% for DBP, though estimates were lower in African populations[61]. However,  
32 27 African data were scarce with one study in Nigeria from Adeyemo et al. (2002) reporting heritability  
33 28 estimates of 34% for SBP and 29% for DBP in 528 families including 1825 individuals[62]. While this  
34 29 was a large sample, heritability of BP has been observed in smaller African studies. For example,  
35 30 Bochud et al. (2005) found a significant heritability estimate for office SBP of 28% in 314 East African  
36 31 (Seychellois) adults from 76 families[32]. However, in this study family members were recruited for  
37 32 having at least two siblings with hypertension and family relationships included first degree (sibling  
38 33 pairs, parent-offspring pairs), second degree (grandparent-grandchild pairs, avuncular pairs i.e.

1  
2  
3 1 uncle/aunt-niece/nephew) and third degree (first cousin pairs) relatives. Our research included only  
4  
5 2 first and second-degree relatives in whom heritability might be expected to be higher, though our  
6  
7 3 overall sample size (n=198) was smaller.

8  
9 4 We also expected to find significant heritability for arterial stiffness within our families. Data from the  
10  
11 5 Framingham Heart Study (1480 individuals from 817 families) suggests around 40% heritability of  
12  
13 6 carotid-femoral pulse wave velocity[22]. While evidence from a study in Brazil (125 families, 1675  
14  
15 7 individuals) shows a lower heritability estimate (27%)[63], though this study also included first, second  
16  
17 8 and third degree relatives. To our knowledge, our results may be some of the first to investigate the  
18  
19 9 intergenerational heritability of carotid-femoral pulse wave velocity as a measure of arterial stiffness  
20  
21 10 in families within South Africa and possibly, in Africa highlighting the need for further work in African  
22  
23 11 families, perhaps increasing sample size through the inclusion of third-degree relatives.

24  
25 12 Given constrained resources for cardiovascular disease treatment in the region, pragmatic and  
26  
27 13 targeted prevention approaches are needed leveraging measurements that may be taken as part of  
28  
29 14 routine clinical practice. Given the heritability of the factors identified in this study, we are not  
30  
31 15 suggesting that people should be screened for these factors to identify at risk children and families.  
32  
33 16 Rather that offspring of adults in whom these factors are found should be targeted for rigorous  
34  
35 17 assessment of risk, especially for raised LVM where this is measured in clinical practice.

### 36 18 *Strengths & Limitations*

37  
38 19 Our findings must be viewed in light of the limitations of this research, most notably the small sample  
39  
40 20 size resulting in high standard deviations observed for phylogenetic variance estimates as well as  
41  
42 21 heritability estimates. However, our heritability estimates from the different estimation methods for  
43  
44 22 each parameter overlap giving confidence for our analysis, and the heritability estimates observed for  
45  
46 23 cIMT and LVMI are similar to many of those reported previously. Additionally, the number of families  
47  
48 24 included in this analysis is similar or more than many other heritability studies, with the random family  
49  
50 25 method increasing the numbers of comparisons available. While our findings contribute to the small  
51  
52 26 but growing evidence base for Africa, further research is needed across the continent to assess the  
53  
54 27 generalisability of our results.

55  
56 28 A further limitation results from the individuals in which we could not collect all phenotypic markers  
57  
58 29 of cardiovascular risk, most notably the SphygmoCor PWV and the echocardiography measures. This  
59  
60 30 difficulty was in part due to excess body mass, for example the mean adult BMI of those with  
31  
32 31 unsuccessful echocardiography measurement was  $40.9 \pm 10.5$  kg/m<sup>2</sup>. We also did not collect data on  
32  
33 32 family history or blood markers of cardiovascular risk such as cholesterol within this study. Future

1  
2  
3 1 studies should consider inclusion of a full CVD risk panel. Our lack of 24 hour ambulatory blood  
4  
5 2 pressure monitoring (ABPM) data within families is also a limitation and future studies should consider  
6  
7 3 the use of ABPM where feasible, as heritability estimates appear higher for ABPM than for office  
8  
9 4 BP[64]. While we have successfully utilised ABPM in South African adults previously[65], this was  
10  
11 5 significantly more challenging in this urban cohort with young children and our attempts were not  
12  
13 6 successful. Community-based support for families during ABPM measurement may be helpful in the  
14  
15 7 future.

16  
17 8 While it is noted that comparison with other studies can be problematic due to different populations,  
18  
19 9 methods, study designs, and environmental influence on phenotypic variance as highlighted by North  
20  
21 10 et al. (2002)[19], we have taken care to compare our results only to studies that are methodologically  
22  
23 11 similar. For example, all comparisons for LVMI heritability presented here include only studies using  
24  
25 12 echocardiographic measurement of LVM, as LVM heritability estimates from electrocardiography may  
26  
27 13 be higher[25]. Furthermore, heritability estimates for IMT often vary between the common carotid  
28  
29 14 artery (CCA) and the internal carotid (ICA), with heritability estimates frequently higher for CCA, so  
30  
31 15 that it is important to compare results for IMT measured in the same location. Furthermore, it is noted  
32  
33 16 that heritability estimates between and within populations are not constant and are influenced by  
34  
35 17 factors such as environmental changes and migration[5]. While this may limit the generalisability of  
36  
37 18 findings from any one study, it remains that heritability estimates for these cardiovascular phenotypes  
38  
39 19 appear largely similar across many of the studies, regions, and populations.

40  
41 20 A key strength of this research is the contribution of evidence for the heritability and intergenerational  
42  
43 21 transmission of cardiovascular health in black African families living in an urban African township,  
44  
45 22 including children prior to adolescence, and the comparison of several different methods to estimate  
46  
47 23 heritability. Further, the high levels of elevated blood pressure and hypertension observed in our  
48  
49 24 population across older and younger adults and in the children reinforce the need for prevention  
50  
51 25 programmes early in life.

## 52 26 **Conclusion**

53  
54 27 Our results suggest that structural cardiovascular indices in the common carotid artery and in the left  
55  
56 28 ventricle of the heart are heritable within African families. Where adults are identified with elevated  
57  
58 29 carotid intima media thickness or left ventricular hypertrophy, screening should be conducted in first  
59  
60 30 and second-degree relatives, especially to identify younger individuals most at risk of later poor  
31  
32 31 vascular health, where prevention efforts may yield the greatest returns. Better understanding of the  
33  
34 32 factors that promote transmission of poor vascular health from one generation to the next will support  
35  
36 33 development of interventions to break the upward spiral of CVD on the continent.



**Contributorship statement:** LJW, JD, SAN and IM conceived the idea for the manuscript and designed the analyses. IM and LJW performed the analyses. LJW, IM, JD, JK, SN, AKR, LS, SC, WS, SAN all contributed to the interpretation of the results. All authors contributed to drafting the manuscript and have seen and approved the final version. LJW is the guarantor for this work and accepts full responsibility for the work.

**Competing Interests:** JD is a member of the Trial Steering Committee for D-Clare (UK MRC funded study: MR/T023562/1) for which no payment is received. She is also a member of the DSMB for NIH funded study (5R01HL144708) for which an honoraria of \$200 is received. She has received the standard \$400 NIH honoraria for being a panel member of their Implementation Science Grant funding stream and is a member of the WHO working group to discern targets for the Diabetes Compact. No other competing interests are declared.

**Funding statement:** This work was supported by the Wellcome Trust (UK) grant number [214082/Z/18/Z].

**Data sharing statement:** Data is available on request from SAN.

## References

1. World Health Organization - *Noncommunicable Diseases (NCD) Country Profile; South Africa*. 2018. p. [https://www.who.int/nmh/countries/zaf\\_en.pdf?ua=1](https://www.who.int/nmh/countries/zaf_en.pdf?ua=1).
2. United Nations - *World Population Prospects: South Africa Life Expectancy 1950-2021*. p. <https://www.macrotrends.net/countries/ZAF/south-africa/life-expectancy>.
3. National Department of Health, Statistics South Africa, South African Medical Research Council, ICF: *South Africa Demographic and Health Survey 2016*.
4. Owolabi, M., et al., *Controlling cardiovascular diseases in low and middle income countries by placing proof in pragmatism*. *BMJ Global Health*, 2016. **1**(3): p. e000105.
5. Visscher, P.M., W.G. Hill, and N.R. Wray, *Heritability in the genomics era — concepts and misconceptions*. *Nature Reviews Genetics*, 2008. **9**(4): p. 255-266.
6. Jacquard, A., *Heritability: one word, three concepts*. *Biometrics*, 1983: p. 465-477.
7. Sailam, V., et al., *Prevalence of emerging cardiovascular risk factors in younger individuals with a family history of premature coronary heart disease and low Framingham risk score*. *Clinical Cardiology: An International Indexed and Peer-Reviewed Journal for Advances in the Treatment of Cardiovascular Disease*, 2008. **31**(11): p. 542-545.
8. Lorenz, M.W., et al., *Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis*. *Circulation*, 2007. **115**(4): p. 459-467.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

9. Aznaouridis, K., S.S. Dhawan, and A.A. Quyyumi, *Cardiovascular Risk Prediction by Measurement of Arterial Elastic Properties and Wall Thickness*, in *Advances in Vascular Medicine*. 2009, Springer. p. 399-421.
10. Vlachopoulos, C., K. Aznaouridis, and C. Stefanadis, *Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis*. *Journal of the American College of Cardiology*, 2010. **55**(13): p. 1318-1327.
11. Gosse, P., *Left ventricular hypertrophy as a predictor of cardiovascular risk*. *Journal of hypertension*, 2005. **23**: p. S27-S33.
12. Peters, S.A., R.R. Huxley, and M. Woodward, *Comparison of the sex-specific associations between systolic blood pressure and the risk of cardiovascular disease: a systematic review and meta-analysis of 124 cohort studies, including 1.2 million individuals*. *Stroke*, 2013. **44**(9): p. 2394-2401.
13. Kagura, J., et al., *Paediatric hypertension in South Africa: An underestimated problem calling for action*. *SAMJ: South African Medical Journal*, 2018. **108**(9): p. 708-709.
14. Hottenga, J.-J., et al., *Heritability and stability of resting blood pressure*. *Twin Research and Human Genetics*, 2005. **8**(5): p. 499-508.
15. Snieder, H., G.A. Harshfield, and F.A. Treiber, *Heritability of blood pressure and hemodynamics in African-and European-American youth*. *Hypertension*, 2003. **41**(6): p. 1196-1201.
16. Kolifarhood, G., et al., *Heritability of blood pressure traits in diverse populations: a systematic review and meta-analysis*. *Journal of human hypertension*, 2019. **33**(11): p. 775-785.
17. Djami-Tchatchou, A.T., et al., *Intrafamilial aggregation and heritability of office- day blood pressure difference in a community of African ancestry: implications for genetic association studies*. *Blood pressure monitoring*, 2014. **19**(6): p. 346-352.
18. Tarnoki, A.D., et al., *Heritability of central blood pressure and arterial stiffness: a twin study*. *J Hypertens*, 2012. **30**(8): p. 1564-71.
19. North, K.E., et al., *Heritability of carotid artery structure and function: the Strong Heart Family Study*. *Arteriosclerosis, thrombosis, and vascular biology*, 2002. **22**(10): p. 1698-1703.
20. Moskau, S., et al., *Heritability of carotid artery atherosclerotic lesions: an ultrasound study in 154 families*. *Stroke*, 2005. **36**(1): p. 5-8.
21. Fox, C.S., et al., *Genetic and environmental contributions to atherosclerosis phenotypes in men and women: heritability of carotid intima-media thickness in the Framingham Heart Study*. *Stroke*, 2003. **34**(2): p. 397-401.
22. Mitchell, G.F., et al., *Heritability and a genome-wide linkage scan for arterial stiffness, wave reflection, and mean arterial pressure: the Framingham Heart Study*. *Circulation*, 2005. **112**(2): p. 194-199.
23. Jin, Y., et al., *Heritability of left ventricular structure and function in Caucasian families*. *European journal of echocardiography*, 2011. **12**(4): p. 326-332.
24. Post, W.S., et al., *Heritability of left ventricular mass: the Framingham Heart Study*. *Hypertension*, 1997. **30**(5): p. 1025-1028.
25. Mayosi, B., et al., *Electrocardiographic measures of left ventricular hypertrophy show greater heritability than echocardiographic left ventricular mass*. *European heart journal*, 2002. **23**(24): p. 1963-1971.
26. Fox, E.R., et al., *Heritability and genetic linkage of left ventricular mass, systolic and diastolic function in hypertensive African Americans (From the GENOA study)*. *American journal of hypertension*, 2010. **23**(8): p. 870-875.
27. Laurent, S. and G. Parati, *Heritability of arterial stiffness and central blood pressure: the Holy Grail for detecting patients at high cardiovascular risk?* *Journal of Hypertension*, 2012. **30**(8).

- 1  
2  
3 1 28. Peterson, V.R., et al., *Intrafamilial aggregation and heritability of left ventricular geometric remodeling is independent of cardiac mass in families of African ancestry*. American journal of hypertension, 2015. **28**(5): p. 657-663.
- 4 2  
5 3  
6 4 29. Peterson, V.R., et al., *Intrafamilial aggregation and heritability of tissue Doppler indexes of left ventricular diastolic function in a group of African descent*. Journal of the American Society of Hypertension, 2016. **10**(6): p. 517-526. e11.
- 7 4  
8 5  
9 6  
10 7 30. Richter, L.M., S.A. Norris, and T. De Wet, *Transition from Birth to Ten to Birth to Twenty: the South African cohort reaches 13 years of age*. Paediatric and perinatal epidemiology, 2004. **18**(4): p. 290-301.
- 11 8  
12 9  
13 10 31. Richter, L.M., S.N. Naicker, and S.A. Norris, *Birth to Twenty Plus: Early health and development from a longitudinal perspective*. Child and Adolescent Development: An expanded focus on public health in Africa, 2018: p. 114.
- 14 11  
15 12  
16 13 32. Bochud, M., et al., *High heritability of ambulatory blood pressure in families of East African descent*. Hypertension, 2005. **45**(3): p. 445-450.
- 17 13  
18 14  
19 15 33. Klein, T.W., *Heritability and genetic correlation: statistical power, population comparisons, and sample size*. Behavior Genetics, 1974. **4**(2): p. 171-189.
- 20 16  
21 17 34. Von Elm, E., et al., *The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies*. Bulletin of the World Health Organization, 2007. **85**: p. 867-872.
- 22 18  
23 19  
24 20 35. *Global Adult Tobacco Survey Collaborative Group. Tobacco Questions for Surveys: A Subset of Key Questions from the Global Adult Tobacco Survey (GATS), 2nd Edition*. Atlanta, GA: Centers for Disease Control and Prevention, 2011.
- 25 21  
26 22  
27 23 36. Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG; *The Alcohol Use Disorders Identification Test, Guidelines for Use in Primary Care, Second Edition, Department of Mental Health and Substance Dependence, World Health Organization, CH-1211 Geneva 27, Switzerland*. ©World Health Organization 2001.
- 28 23  
29 24  
30 25 37. World Health Organization. *Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, 8-11 December 2008*. 2011.
- 31 26  
32 27  
33 28  
34 29 38. World Health Organization *Physical status: The use of and interpretation of anthropometry, Report of a WHO Expert Committee*. 1995: World Health Organization.
- 35 30  
36 31 39. Cole, T.J., et al., *Establishing a standard definition for child overweight and obesity worldwide: international survey*. Bmj, 2000. **320**(7244): p. 1240.
- 37 31  
38 32  
39 33 40. Obe, M.A., *Waist to height ratio and the Ashwell® shape chart could predict the health risks of obesity in adults and children in all ethnic groups*. Nutrition & Food Science, 2005.
- 40 34  
41 35 41. Flynn, J.T., et al., *Clinical practice guideline for screening and management of high blood pressure in children and adolescents*. Pediatrics, 2017. **140**(3).
- 42 36  
43 37 42. Devereux, R.B., et al., *Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings*. The American journal of cardiology, 1986. **57**(6): p. 450-458.
- 44 38  
45 39  
46 40 43. Mosteller, R., *Simplified calculation of body-surface area*. The New England journal of medicine, 1987. **317**(17): p. 1098-1098.
- 47 41  
48 42 44. Shapiro, S.S. and M.B. Wilk, *An analysis of variance test for normality (complete samples)*. Biometrika, 1965. **52**(3/4): p. 591-611.
- 49 43  
50 44 45. Heß, S., *Randomization inference with Stata: A guide and software*. The Stata Journal, 2017. **17**(3): p. 630-651.
- 51 44  
52 45  
53 46 46. Usuzaki, T., M.S.S. Chiba, and S. Hotta, *Random family method: Confirming inter-generational relations by restricted re-sampling*. arXiv preprint arXiv:2002.03467, 2020.
- 54 47  
55 48 47. Hadfield, J.D., et al., *The misuse of BLUP in ecology and evolution*. The American Naturalist, 2010. **175**(1): p. 116-125.
- 56 48  
57 49  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1 48. Morrissey, M., L. Kruuk, and A.J. Wilson, *The danger of applying the breeder's equation in observational studies of natural populations*. *Journal of evolutionary biology*, 2010. **23**(11): p. 2277-2288.
- 2
- 3 49. Zhao, J.H. and P. Congdon, *Bayesian linear mixed models with polygenic effects*. *Journal of Statistical Software*, 2018. **85**(1): p. 1-27.
- 4
- 5 50. Zhao, J., H. Zhao, and L. Zhu, *Pivotal variable detection of the covariance matrix and its application to high-dimensional factor models*. *Statistics and Computing*, 2018. **28**(4): p. 775-793.
- 6
- 7 51. Sinnwell, J.P., T.M. Therneau, and D.J. Schaid, *The kinship2 R package for pedigree data*. *Human heredity*, 2014. **78**(2): p. 91-93.
- 8
- 9 52. Xiang, A.H., et al., *Heritability of Subclinical Atherosclerosis in Latino Families Ascertained Through a Hypertensive Parent*. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 2002. **22**(5): p. 843-848.
- 10
- 11 53. Sacco, R.L., et al., *Heritability and linkage analysis for carotid intima-media thickness: the family study of stroke risk and carotid atherosclerosis*. *Stroke*, 2009. **40**(7): p. 2307-2312.
- 12
- 13 54. Zannad, F., et al., *Genetics strongly determines the wall thickness of the left and right carotid arteries*. *Human genetics*, 1998. **103**(2): p. 183-188.
- 14
- 15 55. Chien, K.-L., et al., *Heritability and major gene effects on left ventricular mass in the Chinese population: a family study*. *BMC cardiovascular disorders*, 2006. **6**(1): p. 1-9.
- 16
- 17 56. Bella, J.N., et al., *Heritability of left ventricular dimensions and mass in American Indians: The Strong Heart Study*. *Journal of hypertension*, 2004. **22**(2): p. 281-286.
- 18
- 19 57. Hank Juo, S.-H., et al., *Heritability of left ventricular mass and other morphologic variables in Caribbean Hispanic subjects: the Northern Manhattan Family Study*. *Journal of the American College of Cardiology*, 2005. **46**(4): p. 735-737.
- 20
- 21 58. Assimes, T.L., et al., *Heritability of left ventricular mass in Japanese families living in Hawaii: the SAPPHiRe Study*. *Journal of hypertension*, 2007. **25**(5): p. 985-992.
- 22
- 23 59. De Simone, G., et al., *Assessment of the interaction of heritability of volume load and left ventricular mass: the HyperGEN offspring study*. *Journal of hypertension*, 2007. **25**(7): p. 1397-1402.
- 24
- 25 60. Hense, H.-W., et al., *The associations of body size and body composition with left ventricular mass: impacts for indexation in adults*. *Journal of the American College of Cardiology*, 1998. **32**(2): p. 451-457.
- 26
- 27 61. Kolifarhood, G., et al., *Heritability of blood pressure traits in diverse populations: a systematic review and meta-analysis*. *Journal of Human Hypertension*, 2019. **33**(11): p. 775-785.
- 28
- 29 62. Adeyemo, A.A., et al., *Heritability of blood pressure in Nigerian families*. *Journal of Hypertension*, 2002. **20**(5): p. 859-863.
- 30
- 31 63. Alvim, R.O., et al., *Heritability of arterial stiffness in a Brazilian population: Baependi Heart Study*. *Journal of hypertension*, 2017. **35**(1): p. 105-110.
- 32
- 33 64. Fava, C., et al., *Heritability of ambulatory and office blood pressure phenotypes in Swedish families*. *Journal of hypertension*, 2004. **22**(9): p. 1717-1721.
- 34
- 35 65. Ware, L.J., et al., *Masked hypertension in low-income South African adults*. *The Journal of Clinical Hypertension*, 2016. **18**(5): p. 396-404.
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47

**Table 1.** Characteristics of the n=65 included families (grandparents, parents and children)

	Grandparents n=65	Parents n=65	Children n=65
Age (years)	56 (10)	29 (0)	7 (3)
Female, n (%)	65 (100)	65 (100)	36 (55)
<i>Anthropometry</i>			
Height (cm)	157.3 (8.1)	159.5 (7.5)	122.5 (16.2)
Weight (Kg)	83.4 (25.9)	72.4 (22.7)	23.8 (9.3)
Mid-upper arm circumference (cm)	36.3 (7.4)	32.8 (8.7)	18.3 (4.4)
Waist circumference (cm)	104.4 (18.2)	88.1 (21.8)	54.8 (12.2)
Waist to height ratio	0.67 (0.12)	0.57 (0.15)	0.44 (0.07)
Body Mass Index (BMI, kg/m <sup>2</sup> )	34.5 (10.6)	29.3 (9.3)	15.7 (2.2)
Underweight, n (%)	1 (2)	1 (2)	9 (14)
Normal weight, n (%)	4 (6)	14 (21)	42 (65)
Overweight, n (%)	12 (18)	19 (29)	12 (19)
Obese, n (%)	48 (74)	31 (48)	2 (3)
<i>Medical history &amp; health behaviour</i>			
Previous diabetes diagnosis, n (%)	4 (6)	0	-
Previous hypertension diagnosis, n (%)	41 (63)	4 (6)	-
On antihypertensive medication, n (%)	40 (62)	2 (3)	-
Currently uses tobacco, n (%)	18 (28)	11 (17)	-
Harmful/hazardous alcohol use, n (%)	10 (15)	22 (34)	-
<i>Sphygmocor: Pulse wave analysis</i>	n=65	n=65	n=62
<i>Brachial measures</i>			
Systolic blood pressure (SBP, mmHg)	133 (28)	117 (18)	103 (11)
Diastolic blood pressure (DBP, mmHg)	80 (16)	73 (12)	63 (9)
Resting heart rate (bpm)	65 (15)	69 (12)	80 (14)
<i>Blood pressure (BP) status, n (%)</i>			
Normal/healthy BP	8 (12)	35 (54)	45 (73)
Elevated BP/Prehypertension	13 (20)	22 (34)	5 (8)
Hypertension	45 (68)	8 (12)	12 (19)
<i>Central measures (c)</i>			
cSBP (mmHg)	126 (26)	106 (16)	92 (12)
cDBP (mmHg)	81 (16)	74 (11)	64 (8)
Pulse pressure (mmHg)	42 (14)	33 (8)	28 (4)
Mean arterial pressure (mmHg)	99 (19)	87 (15)	79 (12)
<i>Sphygmocor: Pulse wave velocity</i>			
Carotid-femoral PWV (m/s)	8.45 (1.83)	6.50 (0.88)	4.33 (0.64)
<i>Ultrasound Carotid Measurements</i>			
Carotid IMT (cIMT left-side mm)	0.66 (0.18)	0.50 (0.10)	0.44 (0.09)
<i>Ultrasound Cardiac Measurements</i>			
LVM indexed to body surface area (LVMI_BSA, g/m <sup>2</sup> )	91.4 (36.4)	82.8 (36.4)	56.4 (21.5)
Left ventricular hypertrophy, n (%)	26 (45)	18 (29)	3 (5)

Data are presented as median (IQR) unless otherwise indicated. For children, LVH was defined as LVMI >95th percentile (109.4 g/m<sup>2</sup>).

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

**Table 2.** Results of random family analysis.

Outcome	Exposure	Observed effect <sup>+</sup> [T(obs)]	c	n	P =c/n
Brachial SBP - GC	Brachial SBP - GP	0.029	3123	5000	0.625
Brachial SBP - GC	Brachial SBP - P	0.123	1027	5000	0.205
Brachial SBP - P	Brachial SBP - GP	0.109	967	5000	0.193
Brachial DBP - GC	Brachial DBP - GP	-0.006	4647	5000	0.929
Brachial DBP - GC	Brachial DBP - P	0.063	2676	5000	0.535
Brachial DBP - P	Brachial DBP - GP	0.001	4970	5000	0.994
Central SBP - GC	Central SBP - GP	-0.005	4649	5000	0.930
Central SBP - GC	Central SBP - P	0.075	2249	5000	0.450
Central SBP - P	Central SBP - GP	0.094	1392	5000	0.278
Central DBP - GC	Central DBP - GP	0.028	3379	5000	0.676
Central DBP - GC	Central DBP - P	0.119	1180	5000	0.236
Central DBP - P	Central DBP - GP	0.006	4702	5000	0.940
PWV - GC	PWV - GP	-0.006	4655	5000	0.931
PWV - GC	PWV - P	0.166	766	5000	0.153
PWV - P	PWV - GP	0.104	1038	5000	0.208
clMT - GC	clMT - GP	0.093	962	5000	0.192
clMT - GC	clMT - P	0.171	1445	5000	0.289
clMT - P	clMT - GP	0.133	83	5000	<b>0.017</b>
LVMI_BSA - GC	LVMI_BSA - GP	-0.076	2301	5000	0.460
LVMI_BSA - GC	LVMI_BSA - P	0.242	213	5000	<b>0.043</b>
LVMI_BSA - P	LVMI_BSA - GP	0.277	102	5000	<b>0.020</b>

GC- grandchild, P- parent, GP- grandparent, SBP – systolic blood pressure, DBP – diastolic blood pressure, clMT – carotid intima media thickness, LVMI\_BSA – left ventricular mass indexed to body surface area. <sup>+</sup>All exposure effects were adjusted for age, height, weight and sex in the regression models. P: the empirical probability value. C: the number of absolute effects  $\geq$  the observed targeted generation effect (e.g. grandparent on grandchild, grandparent on parent etc. as indicated by the formula below). n: the number of generated pseudo random families assessed on the targeted generation effect to determine c, where:  $c = \#\{|T| \geq |T(\text{obs})|\}$

29

**Table 3.** Heritability estimates from different methods

	clMT (mm)			LVMI_BSA (g/m <sup>2</sup> )		
	ReML <sup>1</sup>	MCMC <sup>2</sup>	HMC <sup>3</sup>	ReML	MCMC	HMC
Phylogenetic variance (p)	0.131 (0.114)	0.310 (0.101)	0.175 (0.111)	0.180 (0.172)	0.405 (0.141)	0.240 (0.154)
Error variance	0.426 (0.070)	0.385 (0.056)	0.416 (0.065)	0.660 (0.107)	0.603 (0.085)	0.647 (0.095)
Phenotypic variance	0.556 (0.080)	0.695 (-)	0.591 (-)	0.840 (0.122)	1.008 (-)	0.887 (-)
Heritability ( $h^2$ )	0.234 (0.179)	0.439 (0.098)	0.282 (0.146)	0.214 (0.182)	0.394 (0.099)	0.258 (0.139)
$\beta^4$	0.709 (0.048)	0.705 (0.048)	0.708 (0.047)	0.496 (0.059)	0.496 (0.059)	0.493 (0.060)

<sup>1</sup>Restricted Maximum Likelihood, <sup>2</sup>Markov Chain Monte Carlo method, <sup>3</sup>Hamiltonian Monte Carlo method, <sup>4</sup>coefficient for age which was adjusted for in all models for both vascular markers

30

31

32

33

34

35


36

37


38

Supplementary figure 1 showing the relationships between the heritability parameters for LVMI (adjusted for body surface areas) and carotid IMT (cIMT).

**LVMI**



**cIMT**



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

### Appendix: Additional information on cardiovascular assessment methods

Arterial stiffness (carotid-femoral pulse wave velocity - PWV) was estimated, with tonometry of the carotid artery during inflation of an appropriate size femoral cuff. Pulse wave analysis (for central pressure estimation) and PWV measurement were set at 10 second intervals. Duplicate measures of PWV were taken and if the difference between PWV measures was  $\geq 0.5$  m/s, a third measure was taken and the average of two readings within 0.5m/s of each other used for analysis. All measures were taken on the right side with the participant resting supine for 10 minutes prior to measurement, and using the direct distance method to estimate aortic path length<sup>1</sup>. A total of 4 trained operators performed the PWV measurements after confirming inter-observer variability was acceptable ( $< 0.5$  m/s).

Left ventricular mass (LVM) was measured in 2D mode with transthoracic echocardiography following the American Society of Echocardiography (ASE) protocol<sup>2</sup>. The 2D mode has been shown to be superior to M-Mode for studies of LVM within families<sup>3</sup>. LV mass was assessed at end-diastole perpendicular to the long axis of the left ventricle. The Devereux formula was used to calculate LVM:  $LVM (g) = 0.8 \times 1.04 ((LVDd + IVSd + LVPWd)^3 - LVDd^3) + 0.6$  where LVDd=left ventricular diastolic diameter; IVSd= intraventricular septal diameter, LVPWd= left ventricular posterior wall thickness in diastole<sup>4</sup>.

Carotid intima-media thickness (cIMT) was determined using high resolution B-mode ultrasound employing a linear array 7.5 MHz probe as recommended<sup>5</sup>. Images of at least 1 cm length were obtained of the far wall of the distal portion of the left common carotid artery (CCA) from an optimal angle of incidence (defined as the longitudinal angle of approach where both branches of the internal and external carotid artery are visualised simultaneously). Semi-automated border detection and quality control software were used to calculate cIMT, with at least 3 measurements obtained from the left side and the mean used for analysis. Previous studies have reported no major differences between left and right CCA IMT in associations with cardiovascular disease<sup>6</sup>. All ultrasound measures were taken with the Mindray DC-70 Ultrasound system (Mindray, Shenzhen China).

1. Van Bortel LM, Laurent S, Boutouyrie P, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. *Journal of hypertension* 2012;30(3):445-48.



- 1
- 2
- 3
- 4 2. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by
- 5 echocardiography in adults: an update from the American Society of Echocardiography and the
- 6 European Association of Cardiovascular Imaging. *European Heart Journal-Cardiovascular*
- 7 *Imaging* 2015;16(3):233-71.
- 8 3. Shah SJ, Ober C, Lang RM. Two-Dimensional Echocardiography Is Superior to M-mode for the
- 9 Determination of Left Ventricular Mass: Evidence from a Heritability Study. *Journal of Cardiac*
- 10 *Failure* 2007;13(6):S155.
- 11 4. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular
- 12 hypertrophy: comparison to necropsy findings. *The American journal of cardiology*
- 13 1986;57(6):450-58.
- 14 5. Touboul P-J, Hennerici M, Meairs S, et al. Mannheim carotid intima-media thickness and plaque
- 15 consensus (2004–2006–2011). *Cerebrovascular diseases* 2012;34(4):290-96.
- 16 6. Bots ML, de Jong PT, Hofman A, et al. Left, right, near or far wall common carotid intima-media
- 17 thickness measurements: associations with cardiovascular disease and lower extremity arterial
- 18 atherosclerosis. *Journal of clinical epidemiology* 1997;50(7):801-07.
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

# Reporting checklist for cohort study.

Based on the STROBE cohort guidelines.

## Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cohort reporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

	Reporting Item	Page Number
	<b>Title and abstract</b>	
	Title <a href="#">#1a</a> Indicate the study's design with a commonly used term in the title or the abstract	1

1	Abstract	<a href="#">#1b</a>	Provide in the abstract an informative and	2
2				
3				
4			balanced summary of what was done and	
5				
6			what was found	
7				
8				
9	<b>Introduction</b>			
10				
11				
12	Background /	<a href="#">#2</a>	Explain the scientific background and	3
13				
14	rationale		rationale for the investigation being reported	
15				
16				
17	Objectives	<a href="#">#3</a>	State specific objectives, including any	4
18				
19			prespecified hypotheses	
20				
21				
22	<b>Methods</b>			
23				
24				
25				
26	Study design	<a href="#">#4</a>	Present key elements of study design early	4
27				
28			in the paper	
29				
30				
31	Setting	<a href="#">#5</a>	Describe the setting, locations, and relevant	4
32				
33			dates, including periods of recruitment,	
34				
35			exposure, follow-up, and data collection	
36				
37				
38				
39	Eligibility criteria	<a href="#">#6a</a>	Give the eligibility criteria, and the sources	4
40				
41			and methods of selection of participants.	
42				
43			Describe methods of follow-up.	
44				
45				
46	Eligibility criteria	<a href="#">#6b</a>	For matched studies, give matching criteria	n/a no matching
47				
48			and number of exposed and unexposed	
49				
50				
51				
52	Variables	<a href="#">#7</a>	Clearly define all outcomes, exposures,	5
53				
54			predictors, potential confounders, and effect	
55				
56				
57				
58				
59				
60				

1		modifiers. Give diagnostic criteria, if	
2			
3		applicable	
4			
5			
6	Data sources /	<a href="#">#8</a> For each variable of interest give sources of	5 & appendix
7			
8	measurement	data and details of methods of assessment	
9			
10		(measurement). Describe comparability of	
11		assessment methods if there is more than	
12		one group. Give information separately for	
13		for exposed and unexposed groups if	
14		applicable.	
15			
16			
17			
18			
19			
20			
21			
22	Bias	<a href="#">#9</a> Describe any efforts to address potential	5
23		sources of bias	
24			
25			
26			
27			
28	Study size	<a href="#">#10</a> Explain how the study size was arrived at	4
29			
30			
31	Quantitative	<a href="#">#11</a> Explain how quantitative variables were	5-8
32		handled in the analyses. If applicable,	
33	variables	describe which groupings were chosen, and	
34		why	
35			
36			
37			
38			
39			
40			
41	Statistical	<a href="#">#12a</a> Describe all statistical methods, including	5-8
42		those used to control for confounding	
43	methods		
44			
45			
46	Statistical	<a href="#">#12b</a> Describe any methods used to examine	5-8
47		subgroups and interactions	
48	methods		
49			
50			
51	Statistical	<a href="#">#12c</a> Explain how missing data were addressed	8
52			
53	methods		
54			
55			
56			
57			
58			
59			
60			

1	Statistical	<a href="#">#12d</a>	If applicable, explain how loss to follow-up	n/a no follow-up
2				
3	methods		was addressed	
4				
5				
6	Statistical	<a href="#">#12e</a>	Describe any sensitivity analyses	10 - Table 3 compares
7				
8	methods			three analysis methods
9				
10				
11	<b>Results</b>			
12				
13				
14				
15	Participants	<a href="#">#13a</a>	Report numbers of individuals at each stage	8
16				
17			of study—eg numbers potentially eligible,	
18			examined for eligibility, confirmed eligible,	
19			included in the study, completing follow-up,	
20			and analysed. Give information separately	
21			for for exposed and unexposed groups if	
22			applicable.	
23				
24				
25				
26				
27				
28				
29				
30				
31	Participants	<a href="#">#13b</a>	Give reasons for non-participation at each	8
32				
33			stage	
34				
35				
36				
37	Participants	<a href="#">#13c</a>	Consider use of a flow diagram	n/a – data in text, diagram
38				
39				not included at this stage
40				
41				
42				but can be added
43				
44				
45	Descriptive data	<a href="#">#14a</a>	Give characteristics of study participants (eg	9
46			demographic, clinical, social) and	
47			information on exposures and potential	
48			confounders. Give information separately for	
49			exposed and unexposed groups if	
50			applicable.	
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1	Descriptive data	<a href="#">#14b</a>	Indicate number of participants with missing	8-9
2				
3				
4			data for each variable of interest	
5				
6	Descriptive data	<a href="#">#14c</a>	Summarise follow-up time (eg, average and	n/a
7				
8				
9			total amount)	
10				
11	Outcome data	<a href="#">#15</a>	Report numbers of outcome events or	n/a
12				
13				
14			summary measures over time. Give	
15				
16			information separately for exposed and	
17				
18			unexposed groups if applicable.	
19				
20				
21	Main results	<a href="#">#16a</a>	Give unadjusted estimates and, if applicable,	10-11, Table 2 and Table
22				
23			confounder-adjusted estimates and their	3 - unadjusted estimates
24				
25			precision (eg, 95% confidence interval).	can be provided for
26				
27			Make clear which confounders were	regression analysis as a
28				
29			adjusted for and why they were included	supplementary table if
30				
31				
32				
33				required
34				
35				
36	Main results	<a href="#">#16b</a>	Report category boundaries when	9
37				
38			continuous variables were categorized	
39				
40				
41	Main results	<a href="#">#16c</a>	If relevant, consider translating estimates of	n/a
42				
43				
44			relative risk into absolute risk for a	
45				
46			meaningful time period	
47				
48				
49	Other analyses	<a href="#">#17</a>	Report other analyses done—eg analyses of	8-11
50				
51			subgroups and interactions, and sensitivity	
52				
53			analyses	
54				
55				
56				
57	<b>Discussion</b>			
58				
59				
60				

1	Key results	<a href="#">#18</a>	Summarise key results with reference to	11
2			study objectives	
3				
4				
5				
6	Limitations	<a href="#">#19</a>	Discuss limitations of the study, taking into	13
7			account sources of potential bias or	
8			imprecision. Discuss both direction and	
9			magnitude of any potential bias.	
10				
11	Interpretation	<a href="#">#20</a>	Give a cautious overall interpretation	11-14
12			considering objectives, limitations,	
13			multiplicity of analyses, results from similar	
14			studies, and other relevant evidence.	
15				
16	Generalisability	<a href="#">#21</a>	Discuss the generalisability (external	13
17			validity) of the study results	
18				
19				
20				
21				
22				
23				
24				
25				
26				
27				
28				
29				
30				
31				
32	<b>Other</b>			
33				
34	<b>Information</b>			
35				
36				
37	Funding	<a href="#">#22</a>	Give the source of funding and the role of	1
38			the funders for the present study and, if	
39			applicable, for the original study on which	
40			the present article is based	
41				
42				
43				
44				
45				
46				

#### Notes:

- 6b: n/a no matching
- 8: 5 & appendix
- 12d: n/a no follow-up

- 1 • 12e: 10 - Table 3 compares three analysis methods
- 2
- 3
- 4 • 13c: n/a - not included at this stage but can be added
- 5
- 6
- 7 • 16a: 10-11, Table 2 and Table 3 - unadjusted estimates can be provided for regression analysis
- 8
- 9 as a supplementary table if required
- 10
- 11
- 12
- 13
- 14

15 The STROBE checklist is distributed under the terms of the Creative Commons Attribution License  
16 CC-BY. This checklist was completed on 02. November 2021 using <https://www.goodreports.org/>, a  
17 tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60